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ABSTRACT  
 
  
We investigated the influence of the chondroitin 6-sulfate 
oligosaccharide unit at Ser2750 of hTg on the ability of hTg to induce 
experimental autoimmune thyroiditis in CBA/J(H-2k) mice, by using 
purified preparations of chondroitin 6-sulfate-devoid hTg (hTgCS0), 
chondroitin 6-sulfate-containing hTg (hTgCS), and of the chondroitin 6-
sulfate-containing nonapeptide centred upon Ser2730. Immunization with 
hTgCS was associated with markedly more pronounced infiltration of 
thyroid wih mononuclear cells, in comparison with hTgCS0, and larger 
secondary proliferative responses of splenocytes to both kinds of hTg in 
vitro. Cytokines secreted in the supernatants of splenocyte proliferations 
were predominantly of the TH1 type. Splenocytes from hTgCS-immunized 
mice secreted larger amounts of IFN-γ and IL-2 in response to both kinds of 
hTg, compared with splenocytes from hTgCS0-immunized mice. The 
hTgCSgp glycopeptide elicited the production of significant levels of IFN-γ, 
GM-CSF, IL-6, TNF-α and IL-10, but not of IL-2 and IL-5, both in control 
and immunized groups. The effects of combined hTgCS0 and hTgCSgp on 
IFN-γ and GM-CSF production were additive in hTgCS-immunized mice 
and synergistic in hTgCS0-immunized mice. Synergistic effects were also 
noticed with IL-17 production in both groups. The presence of chondroitin 
sulfate did not influence the sensitization and response to hTg of IL-5-
producing cells. In keeping with the latter results, comparable levels of anti-
hTg antibodies of the IgG class and IgG1 and IgG2a subclasses were found 
in both immune groups. Thus, the chondroitin 6-sulfate oligosaccharide unit 
of hTg deeply affected the immunopathogenicity of hTg in murine EAT, by 
interfering at possibly more than one level in the differentiation process of 
TH1 cells in response to hTg. 
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1 BACKGROUND 
 
 
Thyroglobulin  
 
Thyroglobulin is a large homodimeric glycoprotein, with a Mr of 660,000. 
After being synthesized and assembled into dimers in the endoplasmic reticulum 
and glycosylated in the Golgi apparatus, it is condensed in secretory granules in 
the apical cytoplasm of thyroid follicular cells and secreted in a regulated way in 
the lumen of tyroid follicles. Thyroglobulin is the molecular site of biosynthesis of 
thyroid hormones, which are synthesized through the iodination and coupling of a 
small number of specific tyrosyl residues within the context of the polypeptide 
chains of thyroglobulin. Thyroglobulin is also a major autoantigen, involved in the 
pathogenesis of thyroid autoimmunity (Gentile et al. 2004). 
 
 
Experimental autoimmune thyroiditis (EAT) 
 
Experimental autoimmune thyroiditis (EAT), a murine model of 
Hashimoto’s thyroiditis, can be induced in mice with  haplotypes H-2s  and H-2k by 
immunization with mouse Tg (mTg) or human Tg (hTg) in complete Freund’s 
adjuvant (CFA) or lipopolysaccharide (Rose et al. 1971). EAT is characterized by 
the infiltration of thyroid by mononuclear cells, the production of specific 
antibodies and in vitro cell proliferative responses against Tg. EAT is a T cell-
mediated disease, which can be transferred from mice immunized with mTg to 
syngeneic hosts, by injecting mTg-specific T-cell clones and cytotoxic T 
lymphocytes. CD4+ cells play a dominant role in EAT (Flynn et al. 1989). The 
analysis of the T cell receptor Vβ gene repertoire of thyroid-infiltrating T cells, 
after immunization with Tg or adoptive transfer of mTg-primed T cells, showed 
the clonal expansion of Vβ13+ T cells (Matsuoka et al. 1994; Nakashima et al. 
1996). Also the characterization of mTg-primed T cells, expanded in vitro with 
staphylococcal enterotoxin A, demonstrated the involvement of Vβ13+ and Vβ1+ T 
cells in subsequent thyroiditis transfer (Wan et al. 2001). T helper type-1 responses 
are crucial for thyroiditis development, as underscored by the impaired induction 
of EAT in interleukin-12-deficient C57BL ⁄6 mice (Zaccone et al. 1999) and by the 
association between the IFN-γ gene deletion and the marked reduction of anti-mTg 
IgG1 and IgG2b production, and thyroid infiltration with T, B and plasma cells in 
spontaneous autoimmune thyroiditis (SAT) (Yu et al. 2002). Anti-Tg antibodies 
may also contribute to the pathogenesis of murine autoimmune thyroiditis. A 
selective correlation was found between the activity of EAT and the levels of anti-
idiotypic antibodies to a mAb (3B8G), recognizing a thyroiditogenic tryptic 
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fragment of pTg (Tang et al. 1990). Moreover, some murine mAbs facilitated the 
internalization of mTg by a murine B-cell hybridoma in vitro, and either 
suppressed or enhanced the presentation of the non-dominant pathogenic epitope 
2549–2560 (Dai et al. 1999). In NOD-H-2h4 mice, the levels of mTg-specific IgG1 
and IgG2b autoantibodies produced correlated closely with the severity of SAT 
(Braley-Mullen et al. 1999). Moreover, B cell-deficient NOD-H-2h4 mice 
developed minimal SAT, and B cell function could not be replaced by anti-mTg 
antibodies (Braley-Mullen et al. 2000). 
 
 
Genetic regulation of susceptibility to EAT  
 
The development of  EAT is under the influence of H-2 molecules of the 
murine major hystocompatibility complex (Vladutiu 1989; Beisel et al. 1992). 
High susceptibility strains include C3H(H-2k) and SJL(H-2s), while BALB/C(H-
2d) and B10(H-2b) are relatively resistant. Non-obese diabetic mice (NOD)(H-2g7), 
a strain susceptible to diabetes, are also prone to develop SAT, even though at a 
very low rate with aging (Damotte et al. 1997). However, in NOD(H2h4) 
transgenic mice, which express the H-2Ak allele, diabetes does not develop, while 
thyroiditis occurs at a much higher frequency and is accelerated and enhanced by 
the addition of iodide to drinking water (Braley-Mullen et al. 1999). In the context 
of the “high-responder” haplotype H-2k, the region H-2A of the H-2 complex is the 
major regulator of the susceptibility to EAT (Beisel et al. 1982), even though the 
regions K and D of the H-2 complex also have influence (Kong et al. 1979). The 
primary response of mouse lymphocytes to epithelial syngeneic thyroid cells is 
under a similar control by the H-2 region, and their proliferation seems to be 
triggered  by the recognition of products of the I-A subregion (Salamero and 
Charreire 1983a and 1983b). Therefore, the recognition of a limited number of 
thyroiditogenic epitopes of mTg and hTg by HLA-restricted T lymphocytes seems 
pivotal in the development of EAT. Apparently, H-2 molecules are able to present 
T cell thyroiditogenic epitopes shared by mTg and hTg.  
By using mice characterized by recombination within the H-2 region, differences 
in the genetic influence on the induction of EAT by thyroiditogenic peptides of Tg 
have been observed, in comparison with EAT induction by whole Tg, which is 
under strong influence by H-2Ak products. The rat Tg peptide TgP1 causes EAT 
with a  similar genetic pattern as entire Tg: B10.BR and C3H(H-2k) and SJL(H-2s) 
mice are susceptible, while BALB/C(H-2d) are partially resistant and B10(H-2b) 
are resistant. At variance from EAT induction by intact Tg, EAT induction by 
TgP1 (2495-2511), within the susceptible haplotype H-2k, requires the expression 
of H-2E products, while the H-2D region does not seem to have influence. Such 
divergences probably reflect differences in antigen processing and presentation 
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between Tg and its peptides. The role of H-2E molecules in the presentation of 
peptides such as TgP1 could be masked, if most thyroiditogenic Tg epitopes were 
H-2Ak-restricted. Moreover, the non-immunodominant peptide TgP1 could be 
displaced by other peptides of Tg in the interaction with H2-E molecules, or, 
alternatively, it may not be generated by antigen presenting cells (APC), in the 
course of Tg proteolysis, whereas it may be generated and presented by 
intrathyroidal MHC class I- or class II-positive cells (Chronopoulou et al. 1993). 
Subsequently, it has been demonstrated that the 2496-2504 nonamer was the 
minimal T-cell epitope in TgP1 and could be presented within the context of the 
non-isotypic H-2Ek molecules of C3H(H-2k) mice and H-2As molecules of SJL(H-
2s) mice (Rao et al. 1994). On the other hand, the genetic pattern of mouse 
susceptibility can vary, depending on the pathogenic epitope: rTg peptide 2696-
2713 (TgP2) caused EAT in SJL(H-2s) mice, but not in C3H or B10.BR(H-2k), 
BALB/c(H-2d), and B10(H-2b) mice (Carayanniotis et al. 1994). 
Last, the role of polymorphic genes HLA-BR1 (DR3) in the development of EAT 
following Tg immunization has been addressed using HLA-DR and HLA-DQ 
transgenic mice: immunization of HLA-BR1*0301(DR3) transgenic mice with 
mTg or hTg resulted in severe thyroiditis, while transgenic mice expressing HLA-
BR1*1502(DR2) gene were resistant to EAT (Kong et al. 1996). The introduction 
of the H-2Eak transgene into B10(H2b) or MHC class II-negative Ab0 mice, both 
resistant to EAT, conferred upon them susceptibility to EAT induced by bovine, 
porcine or human Tg, but not murine Tg (Wan et al. 1999). 
 
 
Structure and function of human thyroglobulin (hTg) 
 
 
The Tg gene: structure and evolution 
 
The hTg gene is located on chromosome 8 and it is one of the gratest genes 
known, encompassing 42 exons and spanning more than 300,000 base pairs (Baas 
et al. 1986). About two-thirds of Tg at its amino-terminal side consist of tandemly 
repeated cysteine-rich motifs of various kinds. This portion of the hTg gene 
probably derives from duplication of an ancestral unit made of four exons. 
Subsequent unequal crossing-over events, and the partial “exonization” of some 
introns and the loss of several others, seem to have resulted in the present 
structure. The carboxy-terminal third of Tg is homologous with 
acetylcholinesterase and appears to have been originated from the duplication of 
an ancestral gene, in common with a superfamily of esterases (Takagi et al. 1991; 
Krejci et al. 1991). Thus, Tg appears to be made of two mojeties, an amino-
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terminal one and a carboxy-terminal one, with different evolutionary histories, 
both being able to support the biosynthesis of thyroid hormones.      
 
 
Structure of hTg 
 
The full-length sequence of the hTg mRNA has been determined from 
overlapping cDNA clones (Malthiéry and Lissitzky 1987). It consists of 8448 
nucleotides, including an untranslated 5′-end, an open reading frame, and an 
untranslated 3′-end, and encodes a polypeptide of 2767 amino acids. The first 19 
residues probably represent a  hydrophobic signal sequence and are absent from 
the mature protein, which is composed of 2749 residues and has an expected Mr of 
302,773. Two-thirds of the Tg sequence at its amino-terminal side consist of 
tandemly repeated motifs. The type-1 motif is 60-70-residue long, contains 6 
cysteinyl residues, and is repeated 10 times. The type-2 motif consists of 14 to 17 
amino acids, 2 of which are cysteines, and is repeated 3 times at the center of Tg. 
Five type-3 repeats, subdivided into three subtype-3a repeats, with 8 cysteines 
each, and 2 subtype-3b repeats, with 6 cysteines each, follow in alternating order. 
The type-1 motif is homologous with a cystein-rich motif of the invariant chain 
associated with the class II major histocompatibility antigen (McKnight et al., 
1989). The sequence of 570 amino acids at the COOH-terminus of Tg shows a 
high degree of similarity (up to 60% in some regions) with those of the members 
of a superfamily of lipases and esterases, including the acetylcholinesterase of 
Torpedo californica, human serum cholinesterase, and others (Takagi et al. 1991; 
Krejci et al. 1991). Mature hTg is a mixture of both non-covalent and covalent 
homodimers, having a molecular mass of 330,000. 
 
 
Post-translational modifications of hTg: glycosilation 
 
Carbohydrates contribute about 10 per cent of the Tg mass. Two kinds of 
oligosaccharide units (A and B) are attached by glycosylamine linkages to 
asparagine residues of Tg. High-mannose A units contain a variable number (7-9) 
of mannose residues and 2 N-acetylglucosamine residues. Complex B units 
contain 3 mannose residues and a variable number of N- acetylglucosamine, 
galactose, fucose, and sialic acid residues (Arima et al. 1972). Human Tg also 
contains C and D oligosaccharide units. C units are linked to serine and threonine 
by O-glycosidic bonds and contain galactosamine; D units are chondroitin-6-
sulfate-like oligosaccharides linked to serine and contain a repeating unit of 
glucuronic acid and galactosamine, plus xylose, galactose, and sulfate (Spiro et al. 
1977). 90 per cent of the [35S]-sulfate incorporated into human Tg is equally 
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distirbuted in: a) biantennary B units, containing galactose-3-sulfate, and tri- and 
tetra-antennary B units containing galactose-3-sulfate and N-acetylglucosamine-6-
sulfate; b) chondroitin-6-sulfate-like D units (Spiro and Bhoyroo 1988; Schneider 
et al. 1988). 
 
 
Post-translational modification of hTg: iodination, sulfation and 
hormonogenesis 
 
Iodoamino acids in hTg include monoiodotyrosine (MIT), 3,5-
diiodotyrosine (DIT), and the hormones 3,3′,5-triiodothyronine (T3) and 3,3′,5,5′-
tetraiodothyronine (thyroxine, T4). Under normal conditions, the iodine level 
ranges from 10 to 40 moles of iodine atoms per mole of Tg. MIT, DIT and T4  
appear to be in a precursor-product relationship, in the same order. For an iodine 
content of 0.5 per cent of the Tg weight (25 moles of iodine atoms per mole of 
Tg), 2.5-3 moles of T4 and less of than 1 mole of T3 are formed per mole of 
human Tg. T3 and T4 are formed in Tg via the iodination of specific tyrosyl 
residues and the subsequent transfer of an iodophenoxyl group from a “donor” 
iodothyrosine, which provides the outer ring, to an “acceptor” iodothyrosine, 
which provides the inner ring. The main T4-forming site of Tg has been located at 
tyrosine 5 (Lejeune et al. 1983). T4 formation in human Tg appears to involve 
tyrosine 5 as the acceptor site and tyrosine 130 as the donor site (Marriq et al. 
1991). T4 is also formed at tyrosines 2553 and 2567 (Lamas et al. 1989). 
Dehydroalanine residues have been identified at several positions of Tg from 
various animal species, including  Tyr1375 of bovine Tg (Gentile et al. 1997). 
Several observations lead to the conclusion that the NH2- and COOH-terminal  
regions of Tg represent autonomous hormone-forming domains. A mutation in 
amino acid 296 of Tg, resulting in premature termination and goitre in Dutch 
goats, determined the production of two NH2-terminal fragments, with masses of 
40,000 and 32,000. However, these were capable of efficient thyroid hormone 
production, in the presence of iodide supplementation (Veenboer and de Vijlder 
1993). Thyroid hormones were also efficiently formed by the in vitro iodination of 
a carboxy-terminal fragment of rat Tg fused to Staphylococcal protein A 
(Asunciòn et al. 1992). 
 
 
Chondroitin 6-sulfate oligosaccharide units 
 
In a previous study (Conte et al. 2006), we characterized in detail the O-
linked, type D chondroitin 6-sulfate (C6S) oligosaccharide unit of hTg. We 
developed an ion-exchange chromatography (IEC) method, which permitted us to 
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separate chondroitin 6-sulfate-containing hTg molecules (hTg-CS) from the 
residual hTg molecules (hTg-CS0). By exploiting the changes of electrophoretic 
mobility and staining properties conferred upon the products of limited proteolysis 
of hTg by chondroitin 6-sulfate units, we first restricted the chondroitin 6-sulfate-
containing regions of hTg to a carboxyl-terminal peptide, starting at Thr2514. The 
subsequent purification of a homogeneous, D-glucuronic acid-containing 
nonapeptide (hTg-CSgp), corresponding to hTg residues 2726-2734, permitted us 
to establish Ser2730 as the sole site of chondroitin 6-sulfate addition in hTg.  
In an ample number of hTg preparations, the fraction of hTg-CS in total hTg 
ranged from 32.0 to 71.6%. The C6S unit was composed of a broadly varying 
number of D-glucuronic acid-N-acetyl-D-galactosamine disaccharide units. In 
some goiter hTg preparations with high contents of hTg-CS, hTg-CS heterodimers, 
in which only one hTg subunit contained a C6S chain, coexisted with hTg-CS 
homodimers. In the monomers deriving from the dissociation of hTg-CS in urea, 
the net number of disaccharide units per chondroitin 6-sulfate chain did not exceed 
14. We also showed that hTg-CS has a higher efficiency of hormone formation 
than hTg-CS0, and that the whole unfractionated hTg benefits from this property. 
Thus, chondroitin 6-sulfate addition represents an ergonomic mechanism, by 
which the post-translational modification of a fraction of molecules influences the 
overall function of hTg. The greater advantage in the formation of T3, with respect 
to T4, associated with the chondroitin 6-sulfate unit, and the proximity of the 
attachment site of the latter to the carboxyl terminus of hTg suggest that it may 
influence hormonogenesis by affecting the function of the site of preferential T3 
formation at Tyr2747 (Van de Graaf et al. 2001; Fassler 1988; Lamas 1989). 
Furthermore, we identified two sites, one between Lys2714 and Gly2715 and the 
other between Lys2745 and Thr2746, near the site of chondroitin 6-sulfate 
addition, which were susceptible to limited proteolysis with trypsin. Our data show 
that the former was protected from proteolysis in hTg-CS but not in hTg-CS0. We 
reasoned that the addition of the C6S chain may exert modifying effects in the 
processing of hTg by antigen-presenting cells and in the ability of hTg to function 
as an autoantigen. These may go beyond the possible influences on the proteolytic 
accessibility and/or the recognition of specific T- and B-cell epitopes located in the 
vicinity of the chondroitin 6-sulfate addition site. 
 
 
Effects of chondroitin sulfate proteoglycans 
 
Chondroitin sulfate proteoglycans play important roles in cell adhesion, 
migration, differentiation and proliferation. Several reports indicate that some 
chondroitin sulfate proteoglycans affect the proliferation of a number of cell types. 
Versican 1 and 2 have opposite actions on the proliferation of NIH-3T3 cells: 
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versican 1 induces cell proliferation and inhibits apoptosis, while versican 2 
inhibits cell proliferation and does not affect apoptosis (Sheng et al. 2005). 
TENB2, a chondroitin sulfate proteoglycan identified in prostate cancer, is 
involved in disease progression and in prostatic cell growth control (Glynne-Jones 
et al. 2001). The degradation of chondroitin sulfates A, B and C reduces the 
proliferation and invasion capacity of melanoma cells, while inducing caspase-3 
activity and thus stimulating apoptosis (Denholm et al. 2001). Endothelial cells, 
treated with the same enzymes, behave similarly. Some Authors (Yang et al. 
2004), by studying the chondroitin sulfate proteoglycan of melanoma cells 
(MCSP), demonstrated that it stimulates proliferation, migration and invasion by 
tumor cells, by enhancing FAK and ERK activation. By studying globular 
domains of proteoglycan molecules, specific regions were identified, modulating 
cellular responses, such as apoptosis or cell proliferation (Cattaruzza et al. 2004).  
The action of chondroitin sulfate proteoglycans is often mediated by CD44, the 
most important chondroitin sulfate proteoglycan exposed on the leukocyte surface 
(Taylor and Gallo 2006). CD44 acts mainly as a receptor for hyaluronan, but can 
also bind chondroitin sulfates, heparan sulfates, fibronectin and osteopontin 
(Rudzki and Jothy 1997). CD44 is involved in inflammation, chemotaxis, cell 
proliferation and apoptosis (McVoy and Kew 2005; Castellone et al. 2004; Ayroldi 
et al. 1995). Generally, CD44 is involved in proliferative signalling, whereas it 
provides protection from apoptosis induced by dexamethasone (Ayroldi et al. 
1995). CD44 is coded by a single gene, containing 20 exons; 10 of these exons 
(v1-v10) can be differentially included in the primary transcript, by alternative 
splicing. Splice variants have an important role in tumour progression, being up-
regulated in several human tumours (Ponta et al. 2003). For example, CD44v6 is 
up-regulated in several papillary carcinomas of the thyroid, where it is able to 
modulate tumor invasiveness (Guarino et al. 2005).  
Chondroitin sulfates are related to the differentiation degree of some tumours, such 
as Merkel skin cell carcinoma (Sames et al. 2001) and prostate cancer (Ricciardelli 
et al. 1999). Generally, high levels of proteoglycan chondroitin sulfates are 
predictive of a poor prognosis and malignant progression of the disease. It is 
conceivable that the hTg-CSgp glycopeptide may be involved in the progression of 
thyroid tumours and may induce cellular proliferation and inhibition of apoptosis, 
not only in thyroid cells, where it is expressed, but also in connective tissue and 
endothelial cells. The regulated growth of epithelial tissues depends on the 
controlled proliferation of epithelial cells and the adjacent connective tissue (Popp 
et al. 1996). Some peptides with regulatory functions are produced and released by 
epithelial cells themselves and act as essential parts of autocrine or paracrine 
mechanisms. Thyrotropin (TSH) promotes the growth and the differentiated 
functions of thyrocytes (Roger and Dumont 1984), e.g., thyroglobulin synthesis 
and iodide transport (Weiss et al. 1984; Santisteban et al. 1987).  
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Some functions exerted by TSH are mediated by molecules sythesized by thyroid 
epithelial cells. FRTL-5 cells stimulated with TSH release growth-promoting 
factors, such as insulin-like growth factor II (Maciel et al. 1988) and the secretory 
ectodomain of beta-amyloid precursor proteins (sAPP) (Graebert et al. 1995). A 
regulatory role in the growth of FRTL-5 cells was demonstrated for the latter 
(Popp et al. 1996). Moreover, it was proposed that sAPP operates as an autocrine 
growth factor, mediating the proliferative effect of TSH on neighboring thyroid 
epithelial cells (Pietrzik et al. 1998). The proposed functions of the APP family 
components were in part deduced from the domain structure of different APP 
forms, which include binding sites for collagen, laminin and glycosaminoglycans 
(Kibbey et al. 1993). A chondroitin sulfate modified form of APP, named appican, 
was also characterized (Pangalos et al. 1996). In thyroid cells, APP may act as a 
link between intracellular and extracellular matrix-dependent signals, which 
modulate the proliferative and differentiative status of thyroid cells. Yet, the role 
of the extracellular matrix in the control of thyrocyte growth and differentiation is 
poorly understood. On the other hand, a number of reports have demonstrated the 
role played by components of the extracellular matrix in the control of neural cell 
differentiation and neurite outgrowth. Some authors described both inhibitory and 
stimulatory effects of chondroitin sulfate proteoglycans on cell adhesion and 
neurite outhgrowth in vitro (Anderson et al. 1998). Glycosaminoglycans, 
specifically heparan sulfate, were essential in the action of glial-cell line-derived 
neurotrophic factor (GDNF) on axonogenesis in neurons (Barnett et al. 2002). 
Thyroglobulin secreted by thyroid follicular cells is deposited in the lumen of 
thyroid follicles as a very concentrated colloidal solution, whose concentration is 
increased by the active extrusion of water (Nitsch and Wollman 1987; Chambard 
et al. 1987). In a sense, the colloid substance represents a semisolid extracellular 
matrix in direct contact with the apical functional specializations of thyroid 
epithelial cells. The presence, within the colloid substance, of a relevant proportion 
(from 30 to 70%) of hTg modified by the addition of a C6S oligosaccharide chain 
(hTg-CS) may prompt one to ask whether this hTg isoform may share with other 
proteoglycans of the extracellular matrix any signaling functions towards the 
epithelial cells with which it is in contact, including signaling related with cell 
polarity. It was shown that Tg is able to suppress the expression of thyroid-specific 
genes, such as the sodium/iodide symporter (NIS), thyroperoxidase (TPO), Tg 
itself, and the TSH receptor (TSH-R). Such effects were mediated by Tg binding 
to the apical asialoglycoprotein receptor (ASGPR), while the phosphorylation of 
serine/threonine residues of Tg not only suppressed such effects, but even 
promoted the transcription of thyroid-specific genes (Ulianich et al. 1999). These 
observations may provide grounds for a study of the effects of C6S addition to hTg 
on the modulation of the expression of thyroid-specific functions by hTg. It is 
possible that the addition and/or the elongation of C6S hTg chains be under the 
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regulatory control of TSH, as it occurs with N-linked oligosaccharide units (Di 
Jeso and Gentile 1992). If so, chondroitin 6-sulfate containing hTg (hTg-CS) 
might participate in the autocrine regulation of the differentiated phenotype of 
thyroid cells, under the control of TSH. 
 
 
Involvement of C6S in Experimental Autoimmune Thyroiditis 
 
C6S unit might influence the ability of hTg to induce experimental 
autoimmune thyroiditis (EAT) in genetically susceptible mice in several ways: 
1. The influence of the C6S oligosaccharide chain on the proteolytic susceptibility 
of the extreme carboxy-terminal region of hTg could modify the processing and 
presentation of hTg by antigen-presenting cells (APCs), particularly because the 
site of C6S addition to hTg is localized within an epitope-rich region, harboring 
several T cell- and B cell-related epitopes (Gentile et al. 2004).  O-linked mono- 
and disaccharides in tumor-associated glycoprotein MUC1 restricted the repertory 
of epitopes produced and/or presented in a site-specific manner, either by limiting 
the accessibility of specific cleavage sites to cathepsin L (Hanisch et al. 2003), or 
by preventing epitope recognition by a peptide-specific T cell hybridoma. N-
linked oligosaccharide chains also inhibited the generation of a self epitope from 
glutamate receptor subunit 3 (Gahring et al. 2001), and of cytotoxic lymphocyte 
(CTL)-specific epitopes from influenza A nucleoprotein (Wood 1998). A keratan 
sulfate chain masked an arthritogenic T cell epitope in the G1 domain of aggrecan, 
whereas the enzymatic depletion of multiple chondroitin sulfate side chains 
generated clusters of chondroitin sulfate stubs, which activated specific B cells to 
function as APCs (Glant et al. 1998). Conceivably, the C6S oligosaccharide unit in 
hTg-CS may hamper the processing by APCs of the surrounding hTg region, 
within a range which includes the Lys2714-Gly2715 bond, at the amino side, and 
the Lys2745-Thr2746 bond, at the carboxy side. 
2. Direct effects of chondroitin sulfate oligosaccharide units on cellular immune 
responses have been documented: 
• Ii (invariant chain, CD74) is a non-polymorphic glycoprotein that participates 
in a number of immunological functions. The major functions of Ii are 
mediated through its association with MHC-II heterodimers (Hiltbolt 2002). In 
the ER, newly synthesized Ii self assembles into trimers. Three class II 
heterodimers are sequentially added to one Ii trimer to form a nine-chain 
complex. In the ER, Ii facilitates MHC-II heterodimer assembly and folding 
and occupies the MHC-II-binding groove, preventing premature binding of 
either peptides or unfolded polypeptides. The nonameric complex transits 
through the Golgi and is transported to late endosomes/lysosomes, where Ii is 
degraded, allowing MHC-II to be loaded with peptide. However, it has been 
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shown that a small percentage (2-5%) of Ii molecules associated with class II 
MHC molecules are modified with the addition of a single chondroitin sulfate 
chain at Ser 291. Chondroitin sulfate-containing invariant chain complexes (Ii-
Cs) are transported rapidly from the trans-Golgi network to the cell surface, in 
spite of the presence of an intact endosomal localization signal. In this form, 
they remain associated with class II molecules at the surface of APCs (Sant et 
al. 1985; Miller et al. 1988), where they act as accessory molecules in antigen 
presentation, through interaction with CD44 (Naujokas 2003). Recently, it has 
been demonstrated that the presence of at least one chondroitin sulfate-
containing subunit within the context of Ii/MHC-II nonamers is able to direct 
Ii to the cell surface (Arneson et al. 2007). Enhancing effects of Ii (CD74) on 
T cell mitogenic and allogenic responses occur through the interaction of Ii-
CS (CD74) with CD44 on responding T cells, as they can be inhibited both by 
anti-CD44 antibodies, and by a soluble form of CD44 (CD44Rg) (Naujokas et 
al. 1993). Monoclonal antibodies against CD44 were able to trigger the 
cytotoxic activity of CTL in a TCR-independent manner (Seth et al. 1991). 
Serglycins, small proteoglycans in secretory granules of hematopoietic cells, 
activated the CD3-dependent release of cytokines and proteases from CD44-
positive CTL clones (Toyama-Sorimachi et al. 1995), by interacting with 
CD44 through their chondroitin 4-sulfate and 6-sulfate side chains (Toyama-
Sorimachi et al. 1997). Moreover, the binding of aggrecan to CD44, through 
its chondroitin 4- and 6-sulfate side chains, was able to trigger the 
oligomerization of CD44 molecules and the intracellular signaling (Fujimoto 
et al. 2001). Both CD44v6 and CD44v7 were transiently up-regulated during 
lymphocyte activation. Antibodies to CD44s and CD44v7 inhibited antigenic 
and mitogenic T and B cell responses, while antibodies to CD44v6 selectively 
inhibited T cell responses (Seiter et al. 2000). Finally, cross-linking of 
CD44v6, but not CD44s, promoted TCR/CD3-independent proliferation of T 
lymphoma cells, accompanied by IL-2 production and activation of MAP and 
SAP kinases (Marhaba et al. 2005).  
• More recently, Ii-CS (called CD74) has been identified as the cell-surface 
receptor for Macrophage migration inhibitory factor (MIF) (Leng, 2003). MIF 
promotes pro-inflammatory cytokine production by macrophages, triggers 
proliferation of T cells, and induces the release of nitric oxide, matrix 
metalloproteases, COX-2, and prostaglandin E2. MIF binds to Ii by a high-
affinity interaction and induces the serine phosphorylation of the CD74 
intracytoplasmic domain in a CD44-dependent manner. CD44 might be 
necessary for many, if not all, of MIF’s signal transduction properties. By 
using COS-7/M6 (deficient in both CD74 and CD44) cell lines engineered to 
stably express combinations of CD74, CD44, and CD44D67, some Authors 
found that CD74 alone imparts MIF binding to cells and that the presence of 
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CD44 did not confer additional binding activity over that of CD74 alone. 
There are not evidences for a specific interaction between MIF and CD44; 
however, MIF-mediated ERK1 and ERK2 activation required the expression 
of a full length CD44. MIF stimulation was associated with the PKA-
dependent serine phosphorylation of CD74 and CD44. Investigations with 
siRNA and the kinase inhibitor PP2 indicate that MIF-induced ERK activation 
proceeded via the Src tyrosine kinase, which was previously shown to 
associate physically with the CD44 intracytoplasmic domain (Taher et al. 
1996). Several of the biologic activities of MIF have been shown to proceed 
via ERK activation. These include arachidonic acid metabolism and 
prostaglandin production (via cytoplasmic phospholipase A2 and 
cyclooxygenase-2) (Mitchell et al. 1999; Sampey et al. 2001), regulation of 
p53 activity (Mitchell et al. 2002), and the activation of additional ERK 
effectors, such as the Ets family of transcription factors that regulateToll-like 
receptor expression (Roger et al. 2001). 
• Finally, it has been demostrated that p41 fragment of invariant chain 
(containing an additional 64-amino acid sequence in the lumenal domain) is a 
potent inhibitor of cathepsin L. The additional segment (AS) is cysteine rich, 
and shares significant homology with the type-1 repetitive sequence of 
thyroglobulin (Bevec 1996). These data suggest that p41 may enhance Ag 
presentation, by reducing the proteolytic activity of the Ag-processing 
compartment, thus protecting a subset of antigenic epitopes from excessive 
degradation (Fineschi 1996). 
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2      AIM OF THE STUDY 
 
 
The aim of this study was to determine whether and by which mechanisms 
the chondroitin 6-sulfate oligosaccharide unit of human thyroglobulin may 
modulate the immunopathogenicity of hTg in a murine model of experimental 
autoimmune thyroiditis (EAT). A significant fraction of hTg molecules is 
modified by the addition of a single chondroitin 6-sulfate oligosaccharide unit to 
Ser2730. In an ample number of hTg preparations, a chondroitin 6-sulfate-
containing subfraction of hTg molecules was regularly detected, and its relative 
abundance varied broadly from less than 30% to over 70%. The presence of a 
chondroitin 6-sulfate oligosaccharide unit, thus, is a major source of molecular 
microheterogeneity in hTg. Among the most prominent biochemical effects of 
chondroitin 6-sulfate addition to Ser2730 in hTg, there are the enhancement of the 
T4-forming and, especially, the T3-forming efficiency of hTg, and the protection 
from proteolysis of some closely located sites of tryptic susceptibility. The 
regional location of the chondroitin 6-sulfate oligosaccharide unit of hTg coincides 
with a cluster containing some of the best characterized T cell-dependent epitopes 
in murine models of autoimmune thyroid disease, as well as of some of the most 
prevalent B cell-dependent epitopes in human autoimmune thyroid disease. Such 
circumstances suggest that chondroitin sulfate modification of hTg may influence 
the processing and presentation of hTg epitopes, as it occurs with oliosaccharide 
chains of many glycoproteins. Most importantly, in view of the well documented 
effects that chondroitin sulfate-containing molecules, as the invariant chain (Ii, 
CD74) associated with class II MHC molecules, serglycins, aggrecan, and CD44 
exert on immune cell responses, via their chondroitin sulfate oligosaccharide units, 
it is conceivable that the chondroitin 6-sulfate oligosaccharide unit of hTg may 
also affect the intermolecular and intercellular interactions determining and 
controlling the development of immune responses to hTg. 
Therefore, in order to investigate into further detail the molecular 
determinants of the ability of hTg to induce experimental autoimmune thyroiditis 
in a genetically susceptible strain of CBA/J(H-2k) mice, we have set to determine 
the possible differential effects of the presence of the chondroitin 6-sulfate 
oligosaccharide unit onto the ability of hTg to induce the distinctive histological 
features of EAT and antibody responses against Tg in vivo, as well as the 
characteristic T cell-mediated responses to hTg in vitro, by using purified 
preparations of chondroitin 6-sulfate-devoid hTg (hTgCS0) and chondroitin 6-
sulfate-containing hTg (hTgCS), and of a homogeneously purified hTg nonameric 
glycopeptide (hTgCSgp), containing the chondroitin 6-sulfate unit linked to 
Ser2730. 
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3 MATERIALS AND METHODS 
 
Purification of hTg 
 
hTg was prepared as described (Gentile and Salvatore, 1993) from 
informed euthyroid patients, hemilaryngectomized for non-thyroidal disease, and 
patients undergoing thyroidectomy for non-familial, simple or multinodular goiter. 
Protein concentration was assayed by measuring the optical absorbance at 280 nm. 
Iodine content was assayed as described, using L-thyroxine as the standard 
(Palumbo et al. 1982).  
 
Separation of hTg-CS from hTg-CS0  
 
HTg molecules containing type-D (chondroitin 6-sulfate) oligosaccharide 
units (hTg-CS) were separated from residual hTg molecules, devoid of type-D 
units (hTg-CS0), by ion-exchange chromatography on trimethylamino-substituted 
Q-Sepharose (Q-IEC), using 5-mL HiTrap™ Q-Sepharose HP columns, 
equilibrated in 0.025 M Tris/HCl, pH 7.4 (buffer A). Up to 20 mg of hTg in buffer 
A, plus 0.05 M NaCl, were applied to a column. After washing with buffer A, a 
linear gradient from 0 to 100% of buffer B (1.2 M NaCl in buffer A) was 
developed in 24 min, at the flow rate of 2.5 mL/min. One-mL fractions were 
analyzed, or stored at -80 °C until use.The concentration of bacterial endotoxin in 
hTg, hTgCS and hTgCS0 preparations to be used both for mice immunization and 
secondary splenocyte proliferation assays was measured by the Limulus 
amebocyte lysate test. Sample purity threshold for use with cell cultures was set at 
< 0.01 Endotoxin Units (EU)/mL. 
 
Enzymatic in vitro iodination of hTg, hTg-CS0 and hTg-CS, and analysis of 
the iodine, T3 and T4 content 
 
HTg from goiters, with iodine contents lower than 0.5% on a weight basis 
were iodinated enzymatically in vitro, as previously described (Conte et al. 2006). 
Aliquots of samples were assayed for iodine content, as already described, and for 
protein content, using the BCA Protein Assay Reagent (Bio-Rad Laboratories) and 
bovine serum albumin as the standard. 
 
Purification of the hTg-CSgp glycopeptide  
 
The chondroitin 6-sulfate-containing glycopeptide of hTg (hTgCSgp) was 
purified as previously described (Conte et al. 2006). A 40-mg aliquot of hTgCS 
was denatured and reduced, in 15 mL of 0.3 M Tris/HCl, pH 8.0, 6.0 M 
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guanidine/HCl, 1 x 10-3 M EDTA, 0.01 M dithiothreitol, at 37 °C for 2 h. The 
reduced protein was carboxymethylated with a 5-fold molar excess of 
iodoacetamide, with respect to total –SH groups, at room temperature for 30 min 
in the dark. Alkylation was stopped with excess dithiothreitol. The sample was 
dialyzed against 0.05 M Na phosphate, pH 7.8, and digested with endoproteinase 
Glu-C (protease V8) from Staphylococcus aureus, at the enzyme:substrate weight 
ratio of 1:100, at 37 °C for 18 h. The sample was adjusted with concentrated 
solutions to 0.025 M TrisHCl, 0.1 M NaCl, 2.0 M urea, pH 7.4 (buffer C), and 
loaded onto a 5-mL HiTrap™ Q-Sepharose HP column, equilibrated in the same 
buffer. After washing with buffer C, a gradient was started, from 0 to 100% of 
buffer D (1.2 M NaCl in buffer C) in 55 min, followed by 100% buffer D for 10 
min, at the flow rate of 1 mL/min. One-mL fractions were monitored for the 
optical absorbance at 280 nm and D-glucuronic acid content. A single D-glucuronic 
acid-containing peak was subjected to size exclusion chromatography on a 1.5-by-
100-cm column of Bio-Gel P-2, in 0.01 M NH4HCO3. A D-glucuronic acid-
containing peak, eluted in the void volume, was lyophilized and further purified by 
gel chromatography on a 0.5-by-40-cm column of Sephadex G-50 fine, in 0.01 M 
NH4HCO3. One-mL fractions were monitored for peptide content, by measuring 
the optical absorbance at 220 nm, and D-glucuronic acid content, and a single 
peptide- and D-glucuronic acid-containing peak was lyophilized.   
 
Synthetic peptides 
 
A chondroitin 6-sulfate-devoid nonapeptide homolog of hTg chondroitin 6-
sulfate-containing glycopeptide hTg-CSgp, with the LTAGSGLRE sequence, to be 
used as a negative control for the effects specifically due to the glycosidic unit of 
peptide hTg-CSgp, was synthesized at AnaSpec®, Inc. (San Josè, California). The 
peptide was certified to be endotoxin-free.  
A set of seven partially overlapping C-terminal dodecapeptides 
corresponding to hTg residues: 2702-2713 (C-peptide 1, H-ISSLKTSADGA-OH, 
Mr = 1212.2); 2709-2720 (C-peptide 2, H-SADGAKGGQSAE-OH, Mr = 1077.0); 
2717-2728 (C-peptide 3, H-QSAESEEEELTA-OH, Mr = 1322.2); 2724-2735 (C-
peptide 4, H-EELTAGSGLRED-OH, Mr = 1276.3); 2731-2742 (C-peptide 5, H-
GLREDLLSLQEP-OH, Mr = 1369.5); 2738-2749(T3) (C-peptide 6, H-
SLQEPGSKT-T3-SK-OH, containing T3 at residue 2747, Mr = 1324.3) were also 
synthesized at Anaspec®, Inc. (San Josè, California). The peptides were certified 
to be endotoxin-free. 
 
Conjugation of hTg C-peptides with sulfo-NHS-LC-Biotin 
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Aliquots of 150 nmoles of hTg C-terminal peptides were dissolved in 0.1 
mL of PBS, pH 7.2. Then, 45 μL of 20 mM sulfosuccinimidyl-6-(biotin-amido) 
hexanoate (EZ-Link® Sulfo-NHS-LC-Biotin, Pierce) were added to each sample 
(biotin:peptide molar ratio = 6:1), and mixtures were kept on ice for 2 h. Products 
were filtered on a 1.5-by-100-cm P2 column in 10 mM NH4HCO3, in order to 
remove unreacted biotin. 2-mL fractions were monitored at 220 nm and peaks 
were pooled and liophylized. Samples were assayed with the Lowry protein assay. 
 
Experimental animals 
 
All experiments were conducted using female, 4-week-old CBA/J(H-2k) 
mice genetically susceptible to EAT induction, purchased from Charles River. 
 
EAT induction 
 
Experimental groups of six female, CBA/J(H-2k) mice were immunized at 
day 0 with 100 micrograms of hTgCS0 or hTgCS in Freund's complete adjuvant 
(CFA), containing 3.5 μg/mL of Mycobacterium tuberculosis, in 50 μl of PBS, in 
the dorsal thoracic region. Control mice received PBS in CFA. On day 7, all 
animals were given a supplemental dose of 50 μg of the respective immunogen in 
25 μl of PBS, emulsionated with the same volume of incomplete Freund’s 
adjuvant (IFA). After 30 days, mice were sacrificed by excess anesthesia, and 
blood, spleens and thyroids immediately collected. 
 
Evaluation of EAT  
 
Thyroids were fixed, sliced and stained with May-Grünwald-Giemsa for 
histological examination, or embedded in paraffin for immunoistochemical 
characterization. Mononuclear infiltration of the thyroid was evaluated 
histologically, according to Verginis et al. (2002), in at least 30 sections per 
thyroid lobe per animal, and scored as follows: 0 = no infiltration; 1 = small 
interstitial accumulation between two or more follicles; 2 = one or two foci of 
inflammatory cells more than the size of one follicle; 3 = 10-40% of field area 
occupied by inflammatory cells; 4 = 40-80% of field area infiltrated. 
 
Assay of T4 and T3 in mice sera 
 
The concentrations of fT4 and fT3 in mice sera were determined on 10-100 
μL-aliquots of sera, using solid-phase radio-immunometric assays (Medical 
Systems), with reference curves of 0.3-7.7 pmol for T4, and 30-920 fmol for T3. 
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Lymphocyte proliferation assays 
 
Murine spleens were collected in 5 mL of RPMI 1640 medium, containing 
Na pyruvate, L-glutamine, penicillin and streptomycin. Splenocytes were obtained 
by mechanical disruption of spleens with the upper extremity of a disposable 
syringe plunger and transferred into sterile 50 mL Falcon tubes. In order to remove 
red cells and dead cells, spleen cells were layered onto a cushion of Lympholyte-
M (Cedarlane) and centrifuged at 1000 g for 20 minutes. Live cells were carefully 
collected at the interface with Lympholyte-M, transferred to new tubes and 
resuspended by the addition of 5 mL of medium, diluted 1:100 with PBS and 
counted in a Burker’s cell. After centrifugation, medium was aspirated and cells 
were resuspended in complete RPMI 1640 medium, containing 2% fetal bovine 
serum (FBS), so to obtain a cell density of 2.5 x 106 cells/mL. 200 μL aliquots of 
cell suspension (5 x 105 cells/100μL/well) were cultured for proliferation assays in 
flat-bottom 96-well plates and incubated at 37°C, in a 5% CO2/90% air-humidified 
incubator in the absence or presence of graded doses (0-30 μg) of hTg-CS0 or hTg-
CS, or purified hTgCSgp glycopeptide, or its synthetic non-glycosylated peptide 
homolog (LTAGSGLRE). After 48 h of incubation, 50-μL aliquots of supernatants 
were removed from each well for cytokine assay. 1 μCi of [3H]-thymidine was 
added to each well and incubation prolonged for 16 h, after which the cells were 
blotted onto glass-fiber filters and radioactivity counted in beta counter. All assays 
were performed in triplicate and results were expressed as Stimulation Index (S.I.), 
defined as follows: cpm in the presence of antigen/cpm in the absence of antigen. 
 
Flow-cytometric analysis of CD74 and H2-I expression at the surface of 
isolated dendritic cells isolated from murine spleens 
 
Spleen cell suspensions were prepared and incubated with microbeads 
conjugated with an anti-CD11c monoclonal antibody (MACS-anti-CD11c; 
Miltenyi Biotec). CD11c+ cells were positively selected by high-speed magnetic 
cell sorting (AutoMACS, Miltenyi Biotec). The expression of invariant chain 
(CD74) at the surface of isolated dendritic cells was evaluated, using an anti-CD74 
specific primary goat plyclonal antibody (clone C-16, Santa Cruz Biotechnology), 
recognizing the extracellular carboxy-terminal domain of human CD74, which was 
conjugated with R-phycoerythrin (RPE), using the LYNX Rapid Conjugation Kit 
(AbD Serotec). The expression of MHC II molecules at the DC surface was 
evaluated using a specific APC-conjugated goat anti-H2-A antibody 
(Pharmingen). Dendritic cells were  incubated for 10 minutes in the presence of 
mouse serum, in order to block the Fc receptor. After washing, cells were further 
incubated with 10 μg/well of hTgCS  or hTgCS in 200 μL of RPMI 1640 medium, 
10% fetal calf serum for 20 min at 4° C and washed two times in cold PBS. Data 
0
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were acquired, using a FACSCalibur flow cytometer (Becton Dickinson) and the 
results were analyzed usin the CellQuest Software (Becton Dickinson). 
 
Assay of TH1/TH2 patterns of cytokine secretion 
 
The concentrations of GMC-SF, INFγ, IL-1α, IL-2, IL-4, IL-5, IL-6, IL-10, 
IL-17 and TNF-α in the supernatants of splenocyte proliferative reactions were 
measured, using a multiparametric bead-based flow-cytometric Analyte Detection 
System (FlowCytomix Mouse Th1/Th2 10plex, Bender MedSystems®). 
Measurements were performed using a Dako flow cytometer.
 
Serum antibody assays 
 
Total IgG, IgG1, IgG2a and IgG3 concentrations in mice sera were 
measured by ELISA assay in 96-well plates coated with 1 μg of hTg-CS0, hTg-CS 
or hTg-CSgp as the capture antigen. IgG were assayed on 1:6000 dilutions of sera, 
using biotinylated goat anti-Ig γ chain F(ab’)2 secondary antibodies. IgG1, IgG2a 
and IgG3 were assayed on 1:20000, 1:500 and 1:500 dilutions of sera, 
respectively, using biotinylated rat monoclonal anti-mouse IgG1, IgG2a and IgG3 
antibodies (LO-MG1, LO-MG2a and LO-MG3 clones, Sigma). Detection was 
performed with streptavidine-peroxidase conjugates and orthophenylenediamine. 
For the assay of antibodies against the purified hTgCSgp glycopeptide and 
the synthetic hTg carboxy-terminal peptides (hTg C-peptides), aliquots of 0.5 
μg/well of biotinylated hTgCSgp glycopeptide and 120 pmol of biotinylated hTg 
C-peptides in 100 μL of PBS per well were incubated in Reacti-Bind Neutravidin 
Coated Plates, High-Binding Capacity, 8-well strips (Pierce) over night at 15 °C. 
After washing with PBS 0.05%, Tween-20, plates were incubated with 100 μL of 
1:1000 dilutions of mice sera for IgG and 1:500 of mice sera for IgM detection, in 
blocking buffer for 1 h at room temperature. Secondary antibodies were 
peroxidase-conjugated goat anti-mouse IgG or anti-mouse IgM (Sigma). Assays 
were developed, using orthophenylenediamine as the substrate. 
 
Statistical analysis 
 
Data are expressed as mean ± SD, unless otherwise specified. The 
statistical significance between data obtained in experiments of splenocyte 
proliferation, cytokine assas and serum immunoglobulin concentrations was 
determined by t paired or two-tailed Mann-Withney test, as indicated. A value of p 
< 0.05 was considered to be statistically significant. Hystological evaluation of 
thyroid infiltration was analyzed by the non-parametric Wilcoxon test. 
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4 RESULTS AND DISCUSSION 
 
 
Histological and biochemical evaluation of EAT 
 
The use of the chondroitin 6-sulfate-devoid fraction and of the chondroitin 
6-sulfate-containing fraction of human thyroglobulin (hTg), heretofore referred to 
as hTgCS0 and hTgCS, respectively, for the subcutaneous immunization of 
CBA/J(H-2k) mice in adjuvant, had markedly different impacts on the severity of 
the EAT induced, as judged both from the changes in serum concentrations of the 
thyroid hormone T4 and its precursor T3, and from the histological disease score. 
Thyroid disease was more severe in mice immunized with hTgCS than in those 
immunized with hTgCS0. 
Figure 1 and Table 1 show the disease scores assigned to 48 animals, at the 
end of 3 immunization experiments, by the histological examination of 30 seriate 
sections per thyroid lobe, on the average, on the base of the extent of infiltration of 
thyroid tissue with mononuclear cells. Disease scores 2 and 3, corresponding, 
respectively, to one or more foci of infiltration, more than the size of a thyroid 
follicle, and 10-40% of field area occupied by mononuclear cells, were assigned 
only to mice immunized with hTgCS, whereas mice immunized with hTgCS0 were 
either unaffected or showed very limited thyroid involvement, not exceeding score 
1. A typical aspect of thyroid infiltration with mononuclear cells, which was 
scored 2 in our evaluation, is shown in Figure 2, aside a normally appearing 
thyroid section from a control mouse. 
 
 
 
Fig. 1. Histological EAT score, indicating the severity of mononuclear infiltration of thyroids 
of CBA/J(H-2k) mice immunized with the different forms of hTg. The EAT score was 
calculated, using a modification of the criteria adopted by Verginis et al., in at least 30 seriate 
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sections per thyroid lobe per animal, and scored as follows: 0 = no infiltration; 1 = small interstitial 
accumulation of infiltrating mononuclear cells between two or more follicles; 2 = one or two foci 
of infiltrating mononuclear cells more than the size of one follicle; 3 = 10-40% of field area 
occupied by infiltrating cells; 4 = 40-80% of field area infiltrated. 
 
 
 Number Score 0 Score 1 Score 2 Score 3 
of mice  
Controls 90.0% 10.0% 0% 0% 10 
TgCS0 19 42.1% 57.9% 0% 0% 
TgCS 19 15.8% 68.4% 1  5.3% 0.5%
 
able 1. Number and percent of CBA/J(H-2k) mice assigned disease scores from 0 to 4 in T
three different immunization experiments with hTgCS0 and hTgCS. For score codes, refer to 
the legend to Figure 1. 
 
 
 
 
ig. 2. Representative aspects of thyroid infiltration in EAT, compareed to a normally 
The increased severity of thyroid tissue involvement detected by 
histolo
in mice immunized with hTgCS. 
F
appearing thyroid section from a control animal. The thyroid section shown at right was 
obtained from a CBA/J(H-2k) mice immunized with hTgCS and was scored 2. A normally 
appearing thyroid section from a control animal is shown at left. 
 
 
gical examination was reflected in the differential increases in serum 
concentrations of T4 and T3, which were quite limited and did not reach statistical 
significance in mice immunized with hTgCS0, whereas were large and significant 
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Fig. 3. Serum concentrations of T3 (3,5,5’-triiodothyronine) and T4 (thyroxine) in the sera f 
BA/J(H-2k) mice immunized with the different forms of hTg. Results are expressed as means 
 is known that murine EAT is characterized by low-grade, focal 
mononuclear infiltration of thyroid glands, even in genetically susceptible murine 
strains.
 o
C
± S.D. * indicates the statistical significance between hTgCS and each of the control and hTgCS0 
condition (p <0,05). 
 
 
It
 Thyroid infiltration in experimental animals was even lower, when human 
Tg was used as the immunizing agent, instead of murine Tg, even though it is 
generally accepted that EAT results from the recognition by murine autoreactive T 
cells of epitopes that are conserved between the murine and human species. We 
have shown that hTg is regularly composed of a mixture of hTgCS0 and hTgCS, in 
broadly variable proportions among different individuals. In the light of the data 
here reported, it appears that the induction of autoimmune thyroid disease in 
experimental animals depends prevailingly or solely on the hTgCS fraction of hTg. 
Because investigators of EAT have been using so far unfractionated hTg for their 
experiments, it appears that the variable severity of EAT observed in many studies 
was deeply influenced by the composition of the particular hTg preparations used, 
not only with regard to the percent abundance of hTgCS, but also to the relative 
proportion of heterodimeric and homodimeric hTgCS and to the average chain 
length of the chondroitin 6-sulfate chain linked to each hTg subunit.  
 
 
 24
Proliferative secondary responses of murine splenocytes to hTg 
 
arkedly higher 
 mice immunized with hTgCS, in comparison with mice immunized with 
hTgCS
Proliferative responses both to hTgCS and hTgCS0 were m
in
0. In both groups, the responses to hTgCS0 showed a tendency to inhibition 
at the highest doses, at variance with the responses to hTgCS. 
 
 
 
 
Fig. 4. Proliferative responses by splenic lymphocytes from CBA/J(H-2k) mice immunize
nd restimulated in vitro with the two forms of hTg. Mice were immunized at day 0 with 100 μ
econdary proliferative responses of splenocytes to hTgCSgp and 
TAGSGLRE  
 responses of murine splenocytes were investigated also by 
timulating them with the purified hTg nonapeptide containing the site of 
chondr
 
d 
g a
of hTgCS or hTgCS0 in CFA, followed at day 8 by 50 μg of the same inìmmunnogen in IFA. On 
day 30, mice were sacrificed, spleens removed and splenocytes were restimulated with the 
indicated doses of the same antigen used for immunization. Results are expressed as means ± S.D. 
 
 
S
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Secondary
s
oitin 6-sulfate addition to hTg at Ser2730 (referred to as hTgCSgp). The 
results were similar as those obtained with hTg, as the purified hTgCSgp 
glycopeptide – but not its non-chondroitinated, synthetic peptide homologue 
LTAGSGLRE - elicited much higher, dose-related levels of proliferation in 
animals immunized with hTgCS, in comparison with those immunized with 
hTgCS0. Notably, the splenocytes of control animals also proliferated upon 
restimulation with hTgCSgp, but not with the LTAGSGLRE peptide. 
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Fig. 5. Proliferative secondary responses of splenic lymphocytes of CBA/J(H-2k) mice to 
hTgCSgp and LTAGSGLRE. The splenocytes obtained at sacrifice from control and immun  
BA mice were stimulated in vitro with the purified chondroitin 6-sulfate-containing hTg pe e 
 proliferative responses 
Multiple cytokine concentrations were measured in the supernatants of the 
-2k) mice 
munized with hTgCS0 and hTgCS, by the use of a multiparametric bead-based 
flow c
ized
ptidC
hTgCSgp and its non-glycosylated, synthetic homolog having the LTAGSGLRE sequence. 
Combined results of three esperiments are expressed as means ± S.D. * indicates the statistical 
significance between hTgCS and controls (p < 0.05). 
 
 
Assay of cytokine production in secondary
 
proliferation assays performed with the splenocytes from CBA/J(H
im
ytometric technique. The cytokines assayed were intended to dissect the 
polarization of the CD4+ TH cell-dependent responses, as they included IFN-γ, 
GM-CSF, TNF-α, IL-2, IL-1β, IL-6, IL-4, IL-5, IL-17 and IL-10. Results are 
shown in Figure 6. 
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Fig. 6. Secondary proliferative responses of splenic lymphocytes from CBA/J(H-2k) mice to 
hTgCS0, hTgCS, hTgCSgp or hTgCS0 plus hTgCSgp, also in the presence of the KM114 anti-
CD44 mAb. Results are means ± S.E.M. of five or six animals per experimental group. For the 
sake of clarity, responses to: a) PBS; b) the synthetic, non-glycosylated peptide homolog of 
hTgCSgp (having the LTAGSGLRE sequence) and c) the monoclonal anti-CD44 antibody 
KM114, which were all at baseline values in all conditions, are not shown. All ten cytokines were 
assayed by using a nultiparametric bead-based flow cytometric technique. 
 
 
The following may be noticed in regard to IFN-γ, a typical indicator of TH1 
polarization of the differentiation of CD4+ TH cells (Figure 6, panel A): a) 
secretory responses to both hTgCS0 and hTgCS attained higher levels in hTgCS-
immune, with respect to hTgCS0-immune mice, being absent or very low in 
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control animals; b) the addition of hTgCSgp evoked intense secretory responses of 
closely matching magnitude in all groups, including control animals; c) the 
synthetic, non-glycosylated peptide homolog of hTgCSgp, LTAGSGLRE, had no 
effect of its own, yielding responses close to baseline values in all cases, with all 
cytokines assayed (omitted in Figure 6 for the sake of clarity); d) the combined 
effects of hTgCS0 and hTgCSgp were additive in hTgCS-immunized mice, and 
more than additive in hTgCS0-immune mice, in which the isolated contribution by 
hTgCS0 was lower than in hTgCS-immune mice. Parallel results were obtained 
with GM-CSF (Figure 6, panel B), another typical TH1-like cytokine, although the 
differences between the responses to hTg between the two experimental groups 
did non attain statistical significance; e) the monoclonal antibody KM114, 
reportedly inhibiting the binding of hyaluronic acid to CD44 (Katoh et al. 1995), 
did non have any significant effect on the action of hTgCS and of hTgCSgp. 
The observed effects of hTgCSgp, also viewed in the light of the data 
reported above, concerning the proliferative responses of splenocytes, may 
actually represent the compound result of two distinct actions: 1) a prompt by the 
chondroitin 6-sulfate oligosaccharide unit of hTgCSgp to the proliferation of T 
cells, independent of their activation status, as it was apparent also in control 
splenocytes; 2) an aid to APCs in the sensitization of T cells to hTg, namely to 
antigenic determinants within its peptide mojety, as suggested by the fact that mice 
immunized with hTgCS showed improved secondary responses to both 
chondroitin sulfate-containing and chondroitin sulfate-devoid forms of hTg. This 
latter component was such that could be exerted by the chondroitin 6-sulfate 
oligosaccharide chain also upon secondary restimulation in vitro of splenocytes 
from hTgCS0-immune mice, which had not been exposed to it in vivo at the time 
of immunization. In fact, upon restimulation, the response of hTgCS0-immune 
mice to hTgCS0 in combination with hTgCSgp, once cleared of the individual 
contribution by hTgCSgp, matched the response to hTgCS0 (and hTgCS) observed 
in hTgCS-immune mice. 
IL-2 secretion in response to hTgCS0 and hTgCS was larger in mice 
immunized with the latter, in keeping with the supposed enhancing role of the 
chondroitin 6-sulfate oligosaccharide chain of hTg in the TH1 differentiation of 
hTg-reactive T cells. However, no significant IL-2 production accompanied the 
stimulation with hTgCSgp in any of the experimental groups. This finding 
contrasted with the similarity of the roles commonly attributed to IFN-γ and GM-
CSF and IL-2 in the TH1 polarization of TH cell differentiation. In this regard, it 
has been reported that quantitative ratios of cytokine expression may fluctuate in 
response to changes in activation conditions, such as the quantity and the quality 
of specific or non-specific TCR ligands. In particular, truncated forms of a myelin 
basic protein (MBP) peptide induced the secretion of considerable amounts of 
IFN-γ from MBP-reactive T cells, without inducing IL-2 production or 
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proliferation. By contrast, the staphilococcal enterotoxin superantigen elicited both 
a proliferative response and Il-2 production, without inciting the secretion of IFN-γ 
or TNF-α (Sun et al. 1995). These reports, as well as our observations, illustrate 
the complexities of T cell activation and differentiation, particularly in relation 
with the role played by the modifications of autoantigens and different modes of 
interaction.  
IL-6 and TNF-α invite common comments, as they seemingly obeyed a 
common response pattern: a) no significant differences in the responses to hTg 
between different groups were detected; b) hTgCSgp elicited as strong responses 
as observed with IFN-γ and GM-CSF, in all conditions in which it was present; c) 
no synergistic effects of the combined use of hTgCS0 and hTgCSgp were observed 
in hTgCS0-immune mice, and not even additive effects in hTgCS-immune mice; d) 
the administration of the KM114 anti-CD44 mAb in combination with the 
hTgCSgp glycopeptide was associated with increased IL-6 and TNF-α secretion in 
hTgCS-immune animals, at variance with the production of IFN-γ and GM-CSF. 
Given the predominant origin of IL-6 from stimulated antigen-presenting cells, the 
observations referred above seem to indicate that, aside T cells, the chondroitin 6-
sulfate oligosaccharide chain of hTg was also able to exert its effects on some 
subpopulation(s) of APCs. This is in line with a number of observations 
(Rachmilewitz et al. 1998; Termeer et al. 2001). Proof of this may reside in the 
lack of changes detected, between different experimental groups, in the 
sensitization and responses of splenocytes to hTg, necessarily implying the 
contribution of T cells and, thus, better reflected by changes in IFN-γ, GM-CSF 
and IL-2. It may be argued that TNF-α secretion is normally also a hallmark of 
TH1 cell differentiation. It is possible, however, that, under the circumstances of 
our experiments, most of it derived from activated macrophages, DC or NK cells. 
This, in turn, may reflect a dissociation in the pattern of cytokine production by 
differentiating TH1 cells of a similar kind as the one that was already commented 
upon, between the secretion of IFN-γ and GM-CSF, on one hand, and IL-2, on the 
other hand. 
 Low-grade IL-17 production in response to hTg was detected only in 
hTgCS-immune mice, and low levels of IL-17 were also produced in response to 
hTgCSgp in immunized, but not in control animals. However, a synergistic effect 
between hTgCS0 and hTgCSgp was apparent in immunized mice. IL-17 
production is a hallmark of differentiation of TH17 cells, a specific subpopulation 
of TH cells, which is involved in the control of the inflammatory response, as well 
as in the development of autoimmunity. Even though factors promoting the 
development of the TH1 phenotype are able to suppress the differentiation of TH17 
cells, there is ample evidence supporting the idea that both subpopulations of cells 
may cooperate in the induction of experimental autoimmune encephalitis (EAE) in 
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mice (Bettelli et al. 2007). Our data favour the involvement of IL-17-producing 
cells also in the development of EAT. 
Significant IL-5 production was elicited by both forms hTg forms in both 
groups of immunized mice, but not in control animals, whereas hTgCSgp had no 
effect at all in any of them (Figure 6, panel G). It is quite well established that Tg 
is able to elicit, together with T cell responses, also well defined antibody 
responses, From our data, it was also quite clear that the chondroitin 6-sulfate 
oligosaccharide unit of hTg was not able to affect the differentiation of TH2 cells 
anyhow. By contrast, the levels of IL-4 produced were irrelevant in all groups, 
under all experimental conditions. 
IL-10 was produced in all experimental groups in response to hTgCSgp 
and, to a lesser extent, both forms of hTg. The simultaneous production of 
cytokines characteristic of TH1 cells (IFN-γ and IL-2) and TH2 cells (Il-5 and IL-
10) was previously observed with rat MBP-reactive T cells (Sun et al. 1995). It has 
also been reported that IL-10 has the ability of either enhancing or inhibiting the 
deveolpment of EAE (Sun et al. 1995). Like for T cells producing IL-10 in 
response to MBP, it remains to be established whether the ability of murine T cells 
to produce IL-10 in response to hTgCSgp or to hTgCS0 in the presence of 
hTgCSgp is directly involved in their thyroiditogenic activity. 
Finally, the results obtained with the KM114 anti-CD44 monoclonal 
antibody also deserve comment. The usage of this mAb as a presumptive 
competitor of hTgCSgp was based on the reports concerning, on one hand, the 
involvement of CD44 in the effects of the chondroitin sulfate-containing form of 
the invariant chain (CD74) on mitogenic and allogenic T cell responses (Naujokas 
et al. 1993) and, on the other hand, the inhibitory effect of the KM114 mAb in the 
binding of hyaluronic acid (HA) to CD44 (Zheng et al. 1995). The apparent lack 
of effect of the KM114 mAb in most cytokine secretory responses to hTgCS and 
hTgCSgp, with the only possible exception of IL-2 (Figure 6, panel E), does not 
rule out, in our opinion, the possible involvement of CD44 as a receptor for the 
chondroitin 6-sulfate oligosaccharide chain of hTg. As a matter of fact, the 
interactions of a number of mAbs with CD44 were described, which were very 
selective as to their epitopic specificities and functional consequences. Thus, 
KM114 may still be inhibiting the binding of HA, but not of hTgCSgp, to CD44 
(Zheng et al. 1995). Only further experimentation in CD44-knockout mice may be 
able to prove or rule out the involvement of CD44 in the effects of the chondroitin 
6-sulfate oligosaccharide unit of hTg.  
 
 
Assay of surface expression of H-2 class II and CD74 antigens in isolated DCs 
from CBA/J(H-2k) mice immunized with hTgCS0 and hTgCS 
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We assayed the surface expression of H-2 class II and CD74 (invariant 
chain) antigens in DCs isolated by immunomagnetic positive selection with anti-
CD11c fluorescent antibodies from the spleens of mice immunized with hTgCS0 
and hTgCS, in response to incubation for 2 h with either immunogen. Similar 
levels of class II H-2 expression were detected in all experimental groups, and no 
changes were observed in association with the loading of DCs with the two forms 
of hTg. By contrast, a slight increase in CD74 expression was observed in DCs 
from hTgCS-immunized mice, in comparison with control and hTgCS0-
immunized mice. This experiment was undertaken in order to probe the hypothesis 
that loading DCs with chondroitin sulfate-bearing hTg may someway affect the 
intracellular trafficking of invariant chain (CD74), a fraction of which is also 
modified by the addition of chondroitin sulfate, and whose targeting to the cell 
surface is indeed directed by its chondroitin sulfate-substituted subunits (Arneson 
et al. 2007). Although the results indicate that feeding DCs with hTgCS did not 
alter the intracellular compartmentalization of CD74, they also suggest that some 
changes in environmental conditions, most probably the cytokine milieu in which 
the DCs from hTgCS-immunized mice matured, may have affected the level of 
CD74 expression at their surface. This, in turn, may favourably affect the ability of 
DCs to activate T cell responses, as previously reported (Naujokas et al. 1993). As 
the expression of CD74 in response to such pro-inflammatory stimuli as the IFNγ 
produced by NK, CD4+ and CD8+ cells is coordinately regulated with those of 
MHC class II antigens, HLA-DM and HLA-DQ, it is somewhat surprising that the 
effects seen here on the expression of CD74 were not paralleled by similar effects 
on H-2 class II antigen expression, which may indicate that regulative control 
mechanisms unique to CD74 are involved. 
 
 
 
Fig. 7. Surface expression of H-2I and CD74 by DCs isolated from the spleens of CBA/J(H-
2k) immunized with hTgCS0 and hTgCS and incubated in vitro with both immunogens. 
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Freshly isolated DCs from the spleens of mice sacrificed at day 30 from immunization were 
incubated for 2 h with antigens, after which DCs were plated in 24-well plates at the concentration 
of 2 x 105 cells/well,,incubated with fluorescent antibodies to H2-I or CD74 for 20 min in the dark 
at 4° C and subjected to flow cytometric analysis. Stimulation with 1 μg of LPS was used as a 
positive control. Results are expressed as means ± S.E.M. 
 
 
Production of antibodies against hTgCS0 and hTgCS 
 
Immunization with either form of hTg was accompanied by the production 
of significant amounts of IgG antibodies directed against hTgCS0 and hTg-. Total 
IgG, IgG1 and IgG2a concentrations did not vary between experimental groups. 
No anti-hTg antibodies were detected in controls. 
 
 
 
 
Fig. 8. Concentrations of antibodies of the IgG class and IgG1 and IgG2a subclasses directed 
against hTgCS0 and hTgCS in the sera of CBA/J(H-2k) mice immunized with both antigens. 
Antigens were used at the concentration of 1 μg/well. Results are expressed as means ± S.D. of the 
combined results from 3 (IgG) and 6 experiments (IgG1 and IgG2a). 
 
 
These results outline the lack of significant effects of chondroitin 6-sulfate 
addition to hTg on its ability to elicit the production of antibodies, which was 
already suggested by the lack of effects of hTgCS and of the hTgCSgp 
glycopeptide in the production of type TH2 cytokines in secondary proliferative 
responses of splenocytes from mice immunized with both forms of hTg. 
Next, we investigated whether there were antibodies recognizing the 
hTgCSgp glycopeptide in the sera of mice immunized with hTgCS0 or hTgCS. 
Results are shown in Figure 10. 
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Fig. 9. Concentrations in the sera of CBA/J(H-2k) mice immunized with hTg and controls of 
IgM antibodies against the biotinylated, purified chondroitin 6-sulfate-containing 
glycopeptide hTgCSgp. Combined results of two immunization experiments are expressed as 
means ± S.E.M. 
 
 
The differences between groups were not statistically significant. The 
presence of antibodies recognizing hTgCSgp in the sera of immunized animals did 
not seem to reflect a specific adaptive immune response to the glycosylated 
peptide, as no IgG and comparable levels of IgM antibodies were detected in 
control and immunized animals. This was not surprising, in the light of the 
diffusion and abundance of chondroitin sulfate-containing glycosaminoglycans 
and proteoglycans in the extracellular matrix of connective tissues throughout the 
mouse body. Low levels of IgM antibodies against this kind of polysaccharide 
antigens are usually produced by CD5+ B1 cells, inhabiting the marginal zone of 
spleen and the serous membranes lining body cavities, within the context of type 2 
thymus-independent responses to ubiquitous and abundant self antigens. Because 
these T-independent responses may still entail a limited isotype switch to IgG3 
immunoglobulins, under circumstances in which help is provided by TH cells, 
upon non-clonotypic activation by certain stimuli, whose nature is still poorly 
defined, we also assayed the mice sera for anti-hTgCSgp antibodies of the IgG3 
subclass, but detected none. 
As the chondroitin 6-sulfate oligosaccharide unit of hTg did non appear to 
be involved in the differentiation of Th2 cells and of B cells producing antibodies 
against hTg, and did not seem to constitute or participate in any B cell-dependent 
epitope, either, we next investigated whether it may be affecting the processing 
and/or presentation of neighboring epitopes in the region of the polypeptide chain 
of hTg surrounding the site of chondroitin 6-sulfate addition to Ser2730. 
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Therefore, we designed a set of six dodecameric peptides, overlapping each other 
by four residues at both extremities and spanning the carboxy-terminal region of 
the hTg sequence, between residues 2702-2749, and had them chemically 
synthesized. The extreme carboxy-terminal peptide, containing the preferential site 
of T3 formation in Tg, was synthesized with T3 at position 2747, in view of the 
fact that significant T3 production is normally found at this hormonogenic site in 
vivo, even at low levels of iodine availability. The peptides were conjugated with 
biotin and used in ELISA assays of IgG concentrations in the sera of experimental 
mice. Results are shown in Figure 10. No assayable levels of IgG antibodies were 
found in control animals, even at low serum dilution. Significant levels of IgG 
antibodies were detected only against the carboxy-terminal peptide hTg2738-
2749(T3), and – to a lower extent – the preceding peptide hTg2731-2742. 
 
 
 
 
Fig. 10. Concentrations in the sera of CBA/J(H-2k) mice immunized with hTg and controls of 
IgG antibodies recognizing a set of chemically synthesized, overlapping dodecameric 
peptides, spanning the hTg sequence between amino acid residues 2702-2749. Combined 
results of two immunization experiments are expressed as means ± S.D. * indicates the statistical 
significance between mice immunized with either form of hTg and controls (p < 0.05). 
 
 
The above findings, on one hand, let us rule out that the chondroitin 6-
sulfate oligosaccharide unit of hTg may bear any impact on the availability of B 
cell-dependent epitopes in the neighboring sequence region to processing and 
presentation, at least within the sequence range that we explored. This may hold 
true, notwithstanding the general implications of the post-translational 
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modification with oligosaccharide chains in the antigenicity of proteins, which 
were recalled in the Introduction to the present work. As a matter of fact, the 
inventory and location of B cell-dependent epitopes of Tg from various animal 
species has been thoroughly investigated during the last three decades (reviewed in 
Gentile et al. 2004). The nearest epitope, with respect to the site of chondroitin 6-
sulfate addition to hTg, that was documented in detail, by the use of a set of 
chemically synthesized, overlapping peptides, spanning altogether the entire 
cholinesterase-homologous domain of hTg (residues 2181-2749), was reported at 
residues 2651-2670 (Thrasyvoulides et al. 2001).  
The data presented, however, do not rule out that effects of the chondroitin 6-
sulfate addition on the amenability of hTg to the processing and presentation of B 
cell-dependent epitopes may be resented at other sites of the hTg structure, 
corresponding to more distant regions of the hTg sequence, which may come into 
contact or in the vicinity of the chondroitin 6-sulfate chain, as a consequence of 
the folding and dimerization of hTg polypeptide chains. 
 Concerning the immunogenicity of the T3-containing carboxyterminal 
domain of hTg, ours is the first documentation that immunization of EAT-
susceptible mice with hTg can elicit the production of antibodies directed towards 
the extreme carboxy-terminal sequence of hTg, containing the site of preferential 
T3 formation at Tyr 2747. Other Authors previously reported the detection of 
antibodies in mice immunized with chemically synthesized peptides centered upon 
two major hormonogenic sites of Tg, corresponding to residues 1-12 and 2549-
2560 of hTg (Kong et al. 1995; Wan et al. 1997). A number of evidences suggest 
that Tg antigenicity is influenced by its iodine and hormone content. CBA lymph 
node cells (LNC) primed in vivo with mouse Tg or with the T4-containing hTg 
peptide 2549-2560 were able to adoptively transfer EAT to naive syngeneic hosts, 
following in vitro activation with the peptide (Hutchings et al. 1992). Antigenicity 
appeared to be related as much to the formation of iodothyronine (an event 
naturally occurring in the course of iodination) as to iodination: in fact, hTg 
peptide 2549-2560 containing thyronine (T0) at position 2553 was also able, in 
CBA mice, to induce proliferative responses and activate adoptive transfer of EAT 
by LNCs (primed with mouse Tg or the peptide itself), after in vitro expansion, 
although with lower efficiency than the corresponding T4-containing peptide. Also 
peptides T4(1-12) and T0(1-12), containing T4 or T0 at position 5, respectively, 
stimulated weakly, in rank order of descending potency, mouse Tg-primed T cells 
in vitro (Kong et al. 1995). Conceivably, Tg normally present in low 
concentrations in the serum, which is almost entirely devoid of iodine and appears 
to be secreted from the basolateral pole of the follicular cells, without reaching the 
apical site of iodination (Ikekubo et al. 1981; Schneider et al. 1983), may have 
little immunogenic power, being a self-antigen participating in the process of 
clonal deletion during embryonic development (Savin et al. 1990), whereas the 
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more iodinated and hormone-bearing Tg, normally segregated within thyroid 
follicles and only released into the blood under abnormal conditions, such as 
thyroid cancer and acute or subacute thyroiditis, may activate specific T cells 
recognizing iodination-dependent antigenic determinants. 
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5 CONCLUSIONS 
 
 
The data presented here indicate that the post-translational addition of the 
chondroitin 6-sulfate oligosaccharide chain at Ser2730 of hTg has a profound 
impact on the ability of hTg to induce experimental autimmune thyroiditis in 
genetically sysceptible CBA/J(H-2k) mice. It appears that chondroitin 6-sulfate-
containing hTg molecules (hTgCS), which in previous studies were found to 
represent regularly a broadly variable percentage of whole hTg (Conte et al. 2006), 
may actually be the sole fraction of hTg actually capable of inducing EAT in mice. 
The variability in the percent abundance of hTgCS may explain the poor behavior 
of EAT as an animal model of thyroid autoimmune disease, and the often scarce 
content of hTgCS in whole hTg may help explain the somewhat unpredictable 
outcome of immunization and the focal distribution and limited extension often 
displayed by the experimentally induced disease. In view of the ease of separation 
of hTgCS from the rest of chondroitin 6-sulfate-devoid hTgCS0, our observations 
may be of some value for investigators in the field. 
The mechanism(s) by which the chondroitin 6-sulfate unit of hTg exerts its 
effect(s) on the immunopathogenicity of hTg appear to be complex. The results 
obtained with isolated DCs indicate that they may partly pertain to the cytokine 
milieu in which DC mature and attend to their antigen-presenting duties. 
Undoubtedly, the core effects brought about by the oligosaccharide unit appeared 
to affect T cells. Whichever the effects were on DCs, most probably they were 
indirect reflections of actions directed onto T cells. However, in the light of the 
effects reported for chondroitin sulfate on a variety of cells, including 
macrophages, DC and B cells, this point deserves further investigation, which is to 
include also to the role of NK cells. 
The chondroitin 6-sulfate unit deeply affected the priming of murine T 
cells with hTg, with consequences both on thyroid infiltration and damage in vivo, 
and on secondary lymphocyte responses to hTg in vitro. It appeared capable of 
doing so both as an intrinsic component of hTgCS, and as an independent adjunct 
to hTgCS0, within the experimental setting of proliferative reactions. Moreover, a 
relevant part of its effect(s) was brought about even in the absence of the main 
protein mojety of hTg, i.e., in the form of hTgCSgp, a glycopeptide with a very 
limited nonameric peptidic component, which had no effect of its own. The data 
reported here data raise a number of questions: 1) the first question pertains the 
mechanism(s) whereby the chondroitin 6-sulfate unit of hTgCS normally accesses 
the interaction with T cells: are they related with those which also mediate the 
transport of chondroitin sulfate-containing invariant chain (CD74) molecules to 
the surface of APCs? Do they lead to the immunological synapse?; 2) The second 
major questions relates to the mode of interaction of the chondroitin 6-sulfate unit 
with T cells: Are its actions on proliferation and secretion of resting T cells and of 
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hTg-reactive T cells related? Do they involve the same or different target 
molecules? Is the TCR involved in such interactions, even in a non-specific 
manner? Are non-clonotypic receptors at the surface of T cells involved, on their 
own or together with the TCR? Is CD44 involved, as suggested by prior 
observations? Which is the relationship between the activation state of T cells and 
their sensitivity to the effects of chondroitin 6-sulfate? Answering these questions 
will require the dissection of complex mechanisms at the interface between 
antigen-presenting cells and T cells, including the TCR-mediated activation of T 
cell responses and more than one co-stimulatory mechanism. However, the 
experimental system highlighted by these introductory results may turn out to be a 
privileged standpoint for enriching our understanding of the immunological 
synapse. 
Human thyroglobulin emerges from this study as being seen from a novel 
perspective, that of an antigen which is bearing in itself sort of a “built-in 
adjuvant”, which can make a potentially dangerous trigger of autoimmunity out of 
an otherwise innocuous self antigen. All this may be the consequence of some 
impact which the chondroitin 6-sulfate mojety of hTg seems to have onto T cell 
responses. As the chondroitin 6-sulfate addition to hTg appears to be a regulated 
physiological process, whose extent may vary in relation with factors as yet not 
well understood, it may be of the foremost importance to investigate in further 
detail which pathophysiological conditions may alter the balance between the 
chondroitin 6-sulfate-devoid and chondroitin 6-sulfate-containing fractions of hTg, 
and which relationship may exist between such alterations and autoimmune 
thyroid disease, not only in animal models, but also in humans. 
 38
6 ACKNOWLEDGEMENTS 
 
 
I thank Prof. Giancarlo Vecchio, coordinator of the Molecular Oncology 
and Endocrinology Doctorate who gave me the opportunity to make this important 
experience and to work at the Department of Cellular and Molecular Biology and 
Pathology “L. Califano” of University “Federico II” of Naples. 
 
I thank Prof. Fabrizio Gentile for the opportunity he gave me to work in his 
Laboratory, and for his tutorship in these years. 
 
I want to thank my colleagues at the laboratory, dr. Alessia Arcaro, dr. 
Gianpaolo Cetrangolo, and above all dr. Chiara Luise, who has been a friend more 
than a colleague and support in times of difficulty and an ally in times of joy. 
 
I thank dr. Franco Fulciniti, for his help in the histological evaluation of the 
thyroid disease. 
 
I thank dr. Mario Galgani, for his not only technical but also friendly 
support in last months. 
 
I would like to thank dr. Ilaria Postiglione, dr. Angela Chiaviello and dr. 
Roberta De Mattia who have been companions of many laughs. And I also would 
like to thank dr. Dario Palmieri, who hears and encourages me continuosly. 
 
Special thanks to my colleagues and true friends Mariangela, Roberta, 
Sonia and Irene, for their constant presence in my life, and Domenico, Michele, 
Nicola and Salvo, for having supported me in times of stress. 
   
I also want to thank my “friends of always”, Ida, Francesco, Flavia, 
Alessandro and Andrea, who have always been present in the most important 
occasions of my life. 
 
A special thanks to my best supporter Valerio, for his patience and his 
immense love.  
 
I am specially grateful to my parents and my brothers Fabio, Andrea and 
Stefano. Their encouragement has been essential during all my life.  
 39
7 REFERENCES 
 
 
Anderson RB, Walz A, Holt CE, Key B. Chondroitin sulfates modulate axon 
guidance in embryonic Xenopus brain. Dev Biol 1998;202:235-243. 
 
Arima T and Spiro RG. Studies on the carbohydrate units of thyroglobulin. 
Structure of the mannose-N-acetylglucosamine unit (unit A) of the human and calf 
proteins. J. Biol. Chem. 1972;247:1836-1848 
 
Arima T, Spiro MJ and Spiro RG. Studies on the carbohydrate units of 
thyroglobulin. Evaluation of their microheterogeneity in the human and calf 
proteins. J. Biol. Chem. 1972; 247:1825-1835 
 
Arneson L. et Miller J. The chondroitin sulfate form of invariant chain trimerizes 
with conventional invariant chain and these complexes are rapidly transported 
from the trans-Golgi network to the cell surface. Biochem. J. 2007;406:97-103 
 
Asuncion M, Ingrassia R, Escribano J, Martin U, Mendez F, Di Lauro R, Lamas L. 
Efficient thyroid hormon formation by in vitro iodination of a segment of rat 
thyroglobulin fused to Staphylococcal protein A. Febs Lett 1992; 297:266-270 
 
Ayroldi E, Cannarile L, Migliorati G, Bartoli A, Nicoletti I, Riccardi C. CD44 
(Pgp-1) inhibits CD3 and dexamethasone-induced apoptosis. Blood 86: 
1995;2672-2678  
 
Baas F, van Ommen GJB, Bikker H, Arnberg AC and de Vijlder JJM. The human 
thyroglobulin gene is over 300 kb long and contains introns of up to 64 kb. Nucl. 
Acids Res. 1986;14:5171-5186 
 
Barnett MW, Fisher CE, Perona-Wright G, Davies JA Signalling by glial cell line-
derived neurotrophic factor (GDNF) requires heparan sulphate 
glycosaminoglycan. J Cell Sci 2002 115:4495-4503  
 
Beisel KW, David CS, Giraldo AA, Kong YM and Rose NR. Regulation of 
experimental autoimmune thyroiditis: mapping of susceptibility to the I-A 
subregion of the mouse H-2. Immunogenetics 1982;15:427-430 
Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and 
autoimmunity. Nat Immunol. 2007;4:345-50. 
 
 40
Braley-Mullen H, Sharp GC, Medling B, Tang H. Spontaneous thyroiditis in 
NOD.H-2h4 mice. J. Autoimmun. 1999;12:157-65 
 
Braley-Mullen H and Yu S. Early requirement for B cells for development of 
spontaneous autoimmune thyroiditis in NOD.H-2h4 mice. J. Immunol. 
2000;165:7262-9 
 
Carayanniotis G, Chronopoulou E and Rao V.P. Distinct genetic pattern of mouse 
susceptibility to thyroiditis induced by a novel thyroglobulin peptide. 
Immunogenetics  1994;39:21-28 
 
Castellone MD, Celetti A, Guarino V, Cirafici AM, Basolo F, Giannini R, Medico 
E, Kruhoffer M, Orntoft TF, Curcio F, Fusco A, Melillo RM, Santoro M. 
Autocrine stimulation by osteopontin plays a pivotal role in the expression of the 
mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. 
Oncogene 2004;23:2188-2196 
 
Cattaruzza S, Schiappacassi M, Kimata K, Colombatti A, Perris R. The globular 
domains of PG-M/versican modulate the proliferation-apoptosis equilibrium and 
invasive capabilities of tumor cells. FASEB J  2004;18: 779-781 
 
Chambard M, Mauchamp J, Chabaud O. Synthesis and apical and basolateral 
secretion of thyroglobulin by thyroid cell monolayers on permeable substrate: 
modulation by thyrotropin. J Cell Physiol 1987;133:37-45 
 
Chronopoulou E and Carayanniotis G. H-2Ek expression influences thyroiditis 
induction by the thyroglobulin peptide (2495-2511). Immunogenetics 
1993;38:150-153 
 
Conte M, Arcaro A, D'Angelo D, Gnata A, Mamone G, Ferranti P, Formisano S, 
Gentile F. A single chondroitin 6-sulfate oligosaccharide unit at Ser-2730 of 
human thyroglobulin enhances hormone formation and limits proteolytic 
accessibility at the carboxyl terminus. Potential insights into thyroid homeostasis 
and autoimmunity. J. Biol. Chem. 2006;281(31):22200-22211,  
 
Dai Y, Carayanniotis KA, Eliades P, Lymberi P, Shepherd P, Kong YM, 
Carayanniotis G. Enhancing or suppressive effects of antibodies on processing of a 
pathogenic T cell epitope in thyroglobulin. J. Immunol. 1999;162:6987-92 
 
 41
Damotte D, Colomb E, Cailleau C, Brousse N, Charreire J, Carnaud C. Analysis of 
susceptibility of NOD mice to spontaneous and experimentally induced thyroiditis. 
Eur. J. Immunol. 1997;27:2854-62 
 
Denholm EM, Lin YQ, Silver PJ. Anti-tumor activities of chondroitinase AC and 
chondroitinase B: inhibition of angiogenesis, proliferation and invasion. Eur J 
Pharmacol 2001;416:213-221 
 
Di Jeso B, Gentile F: TSH-Induced galactose incorporation at the NH2-terminus of 
thyroglobulin secreted by FRTL-5 cells. BiochembBiophys Res Commun 
1992;189:1624-1630 
 
Fassler, C A, Dunn, J T, Anderson P C, Fox J W, Dunn A D, Hite L A, Moore R 
C, and Kim P S. Thyrotropin alters the utilization of thyroglobulin's hormonogenic 
sites. J. Biol. Chem. 1988;263,17366-17371 
 
Flynn JC, Conaway DH, Cobbold S, Waldmann H and Kong YM. Depletion of 
L3T4+ and Lyt-2+ cells by rat monoclonal antibodies alters the development of 
adoptively transferred experimental autoimmune thyroiditis. Cell. Immunol. 
1989;122: 377-90 
 
Fujimoto T, Kawashima H, Tanaka T, Hirose M, Toyama-Sorimachi N, 
Matsuzawa Y and Miyasaka M. CD44 binds a chondroitin sulfate proteoglycan, 
aggrecan. Int. Immunol. 2001; 13: 359-366 
 
Gahring L, Carlson NG, Meyer EL, Rogers SW. Granzyme B proteolysis of a 
neuronal glutamate receptor generates an autoantigen and is modulated by 
glycosylation. J Immunol 2001; 166:1433-8. 
 
Gentile F and Salvatore G. Preferential sites of proteolytic cleavage of bovine, 
human and rat thyroglobulin. The use of limited proteolysis to detect solvent-
exposed regions of the primary structure. Eur. J. Biochem. 1993;218:603-621 
 
Gentile F, Ferranti P, Mamone G, Malorni A and Salvatore G. Identification of 
hormonogenic tyrosines in fragment 1218-1591 of bovine thyroglobulin by mass 
spectrometry. Hormonogenic acceptor Tyr-1291 and donor Tyr-1375. 
J.Biol.Chem. 1997a; 272: 639-646 
 
Gentile F., Conte M, Formisano S. Thyroglobulin as an autoantigen: what can we 
learn about immunopathogenicity from the correlation of antigenic properties with 
protein structure? Immunology 2004;112:13-25 
 42
 
Glant TT, Buzas EI, Finnegan A, Negroiu G, Cs-Szabo G, Mikecz K. Critical roles 
of glycosaminoglycan side chains of cartilage proteoglycan (aggrecan) in antigen 
recognition and presentation. J Immunol 1998;160:3812-9. 
 
Glynne-Jones E, Harper ME, Seery LT, James R, Anglin I, Morgan HE, Taylor 
KM, Gee JM, Nicholson RI. TENB2, a proteoglycan identified in prostate cancer 
that is associated with disease progression and androgen independence. Int J 
Cancer 2001;94: 178-184 
 
Graebert KS, Lemansky P, Kehle T, Herzog V. Localization and regulated release 
of Alzheimer amyloid precursor-like protein in thyrocytes. Lab Invest 
1995;72:513-523 
 
Guarino V, Faviana P, Salvatore G, Castellone MD, Cirafici AM, De Falco V, 
Celetti A, Giannini R, Basolo F, Melillo RM, Santoro M. Osteopontin is 
overexpressed in human papillary thyroid carcinomas and enhances thyroid 
carcinoma cell invasiveness. J Clin Endocrinol Metab 2005;90:5270-5278 
 
Hanisch F-G, Schwientek T, Von Bergwelt-Baildon MS, Schultze J, and Finn O. 
O-linked glycans control glycoprotein processing by antigen-presenting cells: a 
biochemical approach to the molecular aspects of MUC1 processing by dendritic 
cells. Eur. J. Immunol. 2003;33:32-42-54 
 
Hutchings, PR, Cooke A, Dawe K, Champion B R, Geysen, M, Valerio R., and I. 
M. Roitt. A thyroxine-containing peptide can induce murine experimental 
autoimmune thyroiditis. J Exp Med 1992;175:869-872. 
 
Ikekubo K, Kishihara M, Sanders J, Jutton J, and A B Schneider. Differences 
between circulating  
and tissue thyroglobulin in rats. Endocrinology 1981;109:427-432. 
Katoh S, Zheng Z, Oritani K, Shimozato T, Kincade PW. Glycosylation of CD44 
negatively regulates its recognition of hyaluronan. J Exp Med. 1995;182(2):419-
29. 
 
Kibbey MC, Jucker M, Weeks BS, Neve RL, Van Nostrand WE, Kleinman HK. 
beta-Amyloid precursor protein binds to the neurite-promoting IKVAV site of 
laminin. Proc Natl Acad Sci U S A. 1993;21:10150-3. 
 
 43
Kong Y M, McCormick D J, Wan Q, Motte R W, Fuller B, Giraldo A A, and 
David CS. Primary hormonogenic sites as conserved autoepitopes on thyroglobulin 
in murine autoimmune thyroiditis. J Immunol 1995;155:5847-5854. 
 
Kong YM, Lomo LC, Motte RW, Giraldo AA, Baisch J, Strauss G, Hämmerling 
GJ and David CS. HLA-DRB1 polymorphism determines susceptibility to 
autoimmune thyroiditis in transgenic mice: definitive association with HLA-
DRB1*0301 (DR3) Gene. J. Exp. Med. 1996;184:1167-1172 
 
Kong, Y. M., David, C. S., Giraldo, A. A., ElRehewy, M., and Rose, N. R. 
Regulation of autoimmune response to mouse thyroglobulin: influence of H-2D-
end genes. J. Immunol. 1979;123:15-18 
 
Krejci E, Duval N, Chatonnet A, Vincens P and Massoulié P. Cholinesterase-like 
domains in enzymes and structural proteins: functional and evolutionary 
relationships and identification of a catalytically essential aspartic acid. Proc. Natl. 
Acad. Sc.i USA 1991;88:6647-6651 
 
Lamas L, Anderson PC, Fox JW and Dunn JT. Consensus sequences for early 
iodination and hormonogenesis in human thyroglobulin. J. Biol. Chem. 
1989;264:13541-13545 
 
Lejeune PJ, Marriq C, Rolland M and Lissitzky S. Amino acid sequence around a 
hormonogenic tyrosine residue in the N-terminal region of human thyroglobulin 
after in vivo and in vitro iodination. Biochem. Biophys. Res. Commun. 1983;114: 
73-80 
 
Maciel RM, Moses AC, Villone G, Tramontano D, Ingbar SH. Demonstration of 
the production and physiological role of insulin-like growth factor II in rat thyroid 
follicular cells in culture. J Clin Invest. 1988;82:1546-1553  
 
 
Malthiéry Y and Lissitzky S. Primary structure of human thyroglobulin deduced 
from the sequence of its 8448-base complementary DNA. Eur. J. Biochem. 
1987;165: 491-498 
 
Marhaba R, Bourouba M, and Zoller M. CD44v6 promotes proliferation by 
persisting activation of MAP kinases. Cell. Signal. 2005;17:961-973 
 
 44
Marriq C, Lejeune PJ, Venot N and Vinet L. Hormone formation in the isolated 
fragment 1-171 of human thyroglobulin involves the couple tyrosine 5 and 
tyrosine 130. Mol. Cell. Endocrinol. 1991;81:155-164 
 
Matsuoka N, Unger P, Ben-Nun A, Graves P and Davies TF. Thyroglobulin-
induced murine thyroiditis assessed by intrathyroidal T cell receptor sequencing. J. 
Immunol. 1994;152:2562-68 
 
McVoy LA, and Kew RR. CD44 and annexin A2 mediate the C5a chemotactic 
cofactor function of the vitamin D binding protein. J Immunol  2005;175:4754-
4760, 
 
Miller J, Hatch JA, Simonis S, Cullen SE. Identification of the glycosaminoglycan 
attachment site of mouse invariant chain proteoglycan core protein by site-direct 
mutagenesis. Proc Natl Acad Sci USA 1988;85:1359-1363 
 
Miyasaka M. CD44 binds a chondroitin sulfate proteoglycan, aggrecan. Int. 
Immunol. 2001;13: 359-366 
 
Naujokas MF, Morin M, Abderson MS, Peterson M, and Miller J. The chondroitin 
sulfate form of invariant chain can enhance stimulation of T cell responses through 
interaction with CD44. Cell 1993;74: 257-68 
 
Nitsch L and Wollman SH: Cell polarity and water transport in thyroid epithelial 
cells in separated follicles in suspension culture. Scann Microsc 1987;1:1279-1286 
 
Palumbo, G., Tecce, M. F., and Ambrosio, G. A non-incinerative rate-sensing 
methods for the determination of iodine in iodoproteins. Anal. Biochem. 
1982;123:183-189 
 
Pangalos MN, Shioi J, Efthimiopoulos S, Wu A, Robakis NK. Characterization of 
appican, the chondroitin sulfate proteoglycan form of the Alzheimer amyloid 
precursor protein. Neurodegeneration 1996;5:445-451 
 
Pietrzik CU, Hoffmann J, Stöber K, Chen CY, Bauer C, Otero DA, Roch JM, 
Herzog V. From differentiation to proliferation: The secretory amyloids. Proc Natl 
Acad Sci USA 1998;95:1770-1775 
 
Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling 
regulators. Nat Rev Mol Cell Biol 2003;4:33-45 
 
 45
Popp GM, Graebert KS, Pietrzik CU, Rosentreter SM, Lemansky P, Herzog V. 
Growth regulation of rat thyrocytes (FRTL-5 cells) by the secreted ectodomain of 
beta-amyloid precursor-like proteins. Endocrinology 1996137:1975-1983  
Rachmilewitz J and Tykocinski ML. Differential effects of chondroitin sulfates A 
and B on monocyte and B-cell activation: evidence for B-cell activation via a 
CD44-dependent pathway. Blood. 1998;92(1):223-9. 
 
Rao VP, Balasa B and Carayanniotis G. Mapping of thyroglobulin epitopes: 
presentation pf a 9mer pathogenic peptide by different mouse MHC class II 
isotypes. Immunogenetics 1994;40:352-359 
 
Ricciardelli C, Quinn DI, Raymond WA, McCaul K, Sutherland PD, Stricker PD, 
Grygiel JJ, Sutherland RL, Marshall VR, Tilley WD, Horsfall DJ. Elevated levels 
of peritumoral chondroitin sulfate are predictive of poor prognosis in patients 
treated by radical prostatectomy for early-stage prostate cancer. Cancer Res 
1999;59: 2324-2328 
 
Roger and Dumont 1984 Roger PP, Dumont JE. Factors controlling proliferation 
and differentiation of canine thyroid cells cultured in reduced serum conditions. 
Mol Cell Endocrinol 1984;36: 79-93 
 
Rose NR, Twarog FJ and Crowle AJ. Murine thyroiditis: importance of adjuvant 
and mouse strain for induction of thyroid lesions. J. Immunol. 1971;106:698-704 
 
Rudzki Z and Jothy S. CD44 and the adhesion of neoplastic cells. Mol Pathol 
1997;50: 57-71 
 
Salamero J, Charreire J. Syngeneic sensitization of mouse lymphocytes on 
monolayers of thyroid epithelial cells. V. The primary syngeneic sensitization is 
under I-A subregion control. Eur J Immunol. 1983a;13:948-51 
 
Salamero I and Charreire J. Syngeneic sensitization of mouse lymphocytes on 
monolayers of thyroid epithelial cells. Relation to H-2 haplotypes. Cell. Immunol. 
1983b;78:387-391 
 
Sames K, Schumacher U, Halata Z, Van Damme EJ, Peumans WJ, Asmus B, Moll 
R, Moll I. Lectin and proteoglycan histochemistry of Merkel cell carcinomas. Exp 
Dermatol 2001;10: 100-109 
 
 46
Sant AJ, Schwartz BD, Cullen SE. Cellular distribution of the Ia-associated 
chondroitin sulfate proteoglycan. J Immunol 1985; 135:408-15. 
 
Santisteban P, Kohn LD, Di Lauro R. Thyroglobulin gene expression is regulated 
by insulin and insulin-like growth factor I, as well as thyrotropin, in FRTL-5 
thyroid cells. J Biol Chem. 1987;25;262(9):4048-52. 
 
Savin S, Sofronic L, and J Sinadinovic. Occurrence of antithyroxine antibodies in 
rabbits immunized with iodine-poor human thyroglobulin. Exp Clin Endocrinol 
1990;95:375-383. 
 
Schneider A B, Ikekubo K, and K. Kuma. Iodine content of serum thyroglobulin in 
normal individuals and patients with thyroid tumors. J Clin Endocrinol Metab 
1983;57:1251-1256. 
 
Schneider AB, McCurdy A, Chang T, Dudlak D and Magner J. Metabolic labeling 
of human thyroglobulin with (35S)-sulfate: incorporation into chondroitin 6-sulfate 
and endoglycosidase-F-susceptible carbohydrate units. Endocrinology 
1988;122:2428-2435 
 
Seiter S, Schimdt DS, Zöller M. The CD44 variant isoforms CD44v6 and CD44v7 
are expressed by distinct leukocytes subpopulations and exert non-overlapping 
functional activities. Int Immunol 2000;12:37-49 
 
Seth A, Gote L, Nagarkatti M, Nagarkatti PM. T-cel-receptor-independent 
activation of cytolytic activaty T cytotoxic lymphocytes through mediated CD44 
and gp90MEL14 Proc Natl Acad Sci USA 1991;88:7877-7881 
 
Sheng W, Wang G, Wang Y, Liang J, Wen J, Zheng PS, Wu Y, Lee V, 
Slingerland J, Dumont D, Yang BB. The roles of versican V1 and V2 isoforms in 
cell proliferation and apoptosis. Mol Biol Cell 2005;16:1330-40,  
 
Spiro MJ. Presence of a glucuronic acid-containing carbohydrate unit in human 
thyroglobulin. J. Biol. Chem. 1977;252:5424-5430 
 
Spiro RG and Bhoyroo VD. Occurrence of sulfate in the asparagine-linked 
complex carbohydrate units of thyroglobulin. Identification and localization of 
galactose 3-sulfate and N-acetylglucosamine 6-sulfate residues in the human and 
calf proteins. J. Biol. Chem. 1988;263:14351-14358 
 
 47
Sun D, Hu XZ, Shah R, Coleclough C.The pattern of cytokine gene expression 
induced in rat T cells specific for myelin basic protein depends on the type and 
quality of antigenic stimulus. Cell Immunol 1995;166: 1-8 
 
Takagi Y, Omura T and Go M. Evolutionary origin of thyroglobulin by 
duplication of esterase gene. FEBS Lett. 1991;282:17-22 
 
Tange H, Bedin C, Texier B and Charreire J. Autoantibody specific for a 
thyroglobulin epitope inducing experimental autoimmune thyroiditis or its anti-
idiotype correlates with the disease. Eur. J. Immunol. 1990;20:1535-9 
 
Taylor KR, and Gallo RL. Glycosaminoglycans and their proteoglycans: host-
associated molecular patterns for initiation and modulation of inflammation. 
FASEB J 2006;20:9-22 
Termeer C, Johannsen H, Braun T, Renkl A, Ahrens T, Denfeld RW, Lappin MB, 
Weiss JM, Simon JC.J The role of CD44 during CD40 ligand-induced dendritic 
cell clustering and maturation. Leukoc Biol. 2001;70(5):715-22. 
 
Thrasyvoulides A, Sakarellos-Daitsiotis M, Philippou G, Souvatzoglou A, 
Sakarellos C, Lymberi P. B-cell autoepitopes on the acetylcholinesterase-
homologous region of human thyroglobulin: association with Graves' disease and 
thyroid eye disease. Eur J Endocrinol. 2001;145(2):119-27  
 
Toyama-Sorimachi N, Sorimachi H, Tobita Y,  Kitamura F, Yagita H, Suzuki K, 
Miyasaka M. A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-
specific proteoglycan. J. Biol. Chem. 1995;270:7437-7444 
 
Toyama-Sorimachi N, Kitamura F, Habuchi H, Tobita Y, Kimata K and Miyasaka 
M. Widespread expression of chondroitin sulfate-type serglycins with CD44 
binding ability in hematopoietic cells. J. Biol. Chem. 1997;272:26714-26719 
 
Ulianich L, Suzuki K, Mori A, Nakazato M, Pietrarelli M, Goldsmith P, Pacifico 
F, Consiglio E, Formisano S, Kohn LD. Follicular thyroglobulin (TG) suppression 
of thyroid-restricted genes involves the apical membrane asialoglycoprotein 
receptor and TG phosphorylation. J Biol Chem  1999;274:25099-107, 
 
Van de Graaf, S. A. R., Ris-Stalpers, C., Pauws, E., Mendive, F. M., Targovnik, H. 
M., and de Vijlder, J. J. M. Up to date with human thyroglobulin. J. Endocrinol. 
2001;170,307-321 
 
 48
Veenboer GJM and de Vijlder JJM. Molecular basis of the thyroglobulin synthesis 
defects in Dutch goats. Endocrinology 1993;132:377-81 
 
Verginis P , Stanford MM and Carayanniotis G. Delineation of five thyroglobulin 
T cell epitopes with pathogenic potential in experimental autoimmune thyroiditis. 
J. Immunol. 2002;169:5332-7 
 
Vladutiu AO. Experimental autoimmune thyroiditis in mice chronically treated 
from birth with anti-IgM antibodies. Cell. Immunol. 1989;121:49-59 
 
Wan Q, Shah R, McCormick DJ, Lomo LC, Giraldo AA, David DS and Kong 
YM. H2-E transgenic class II-negative mice can distinguish self from nonself in 
susceptibility to heterologous thyroglobulins in autoimmune thyroiditis. 
Immunogen. 1999;50: 22-30 
 
Wan Q, Kita M, Flynn JC et al. Participation of Vb13+ and Vb1+ T cells in 
transfer thyroiditis after activation of mouse thyroglobulin-primed T cells by 
superantigen staphylococcal enterotoxin A. Cell. Immunol. 2001;213:149-57 
 
Weiss SJ, Philp NJ, Grollman EF. Iodide transport in a continuous line of cultured 
cells from rat thyroid. Endocrinology 1984;114:1090-1098 
 
Wood 1998 Wood P, Elliott T. Glycan-regulated antigen processing of a protein in 
the endoplasmic reticulum can uncover cryptic cytotoxic T cell epitopes. J Exp 
Med 1998;188:773-778  
 
Yang J, Price MA, Neudauer CL, Wilson C, Ferrone S, Xia H, Iida J, Simpson 
MA, McCarthy JB. Melanoma chondroitin sulfate proteoglycan enhances FAK 
and ERK activation by distinct mechanisms. J Cell Biol 2004;165: 881-891 
 
Yu S, Sharp GC and Braley-Mullen H. Dual roles for IFN-gamma, but not for IL-
4, in spontaneous autoimmune thyroiditis in NOD.H-2h4 mice. J. Immunol. 
2002;169:3999-4007 
 
Zaccone P, Hutchings P, Nicoletti, Penna G, Adorini L, and Cooke A. The 
involvement of IL-12 in murine experimentally induced autoimmune thyroid 
disease. Eur. J. Immunol. 1999;29:1933-42 
 
Zheng Z, Katoh S, He Q, Oritani K, Miyake K, Lesley J, Hyman R, Hamik A, Parkhouse 
RM, Farr AG, et al. Monoclonal antibodies to CD44 and their influence on hyaluronan 
recognition. J Cell Biol. 1995;130(2):485-95 
 49
A Single Chondroitin 6-Sulfate Oligosaccharide Unit
at Ser-2730 of Human Thyroglobulin Enhances
Hormone Formation and Limits Proteolytic
Accessibility at the Carboxyl Terminus
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We localized the site of type D (chondroitin 6-sulfate) oligo-
saccharide unit addition tohuman thyroglobulin (hTg). hTgwas
chromatographically separated into chondroitin 6-sulfate-con-
taining (hTg-CS) and chondroitin 6-sulfate-devoid (hTg-CS0)
molecules on the basis of their D-glucuronic acid content. In an
ample number of hTg preparations, the fraction of hTg-CS in
total hTg ranged from 32.0 to 71.6%. By exploiting the electro-
phoretic mobility shift and metachromasia conferred by chon-
droitin 6-sulfate upon the products of limited proteolysis of
hTg, chondroitin 6-sulfate was first restricted to a carboxyl-ter-
minal region, starting at residue 2514. A single chondroitin
6-sulfate-containing nonapeptide was isolated in pure form
from the products of digestion of hTg with endoproteinase
Glu-C, and its sequence was determined as LTAGXGLRE (resi-
dues 2726–2734, X being Ser2730 linked to the oligosaccharide
chain). In an in vitro assay of enzymatic iodination, hTg-CS pro-
duced higher yields of 3,5,5-triiodothyronine (T3) (171%) and
3,5,3,5-tetraiodothyronine (T4) (134%) than hTg-CS0. Unfrac-
tionated hTg behaved as hTg-CS. Thus, chondroitin 6-sulfate
addition to a subset of hTgmolecules enhanced the overall level
of T4 and, in particular, T3 formation. Furthermore, the chon-
droitin 6-sulfate oligosaccharide unit of hTg-CS protected pep-
tide bond Lys2714–Gly2715 from proteolysis, during the limited
digestion of hTg-CS with trypsin. These findings provide
insights into themolecular mechanism of regulation of the hor-
monogenic efficiency and of the T4/T3 ratio in hTg. The poten-
tial implications in the ability of hTg to function as an autoanti-
gen and into the pathogenesis of thyroidal and extra-thyroidal
manifestations of autoimmune thyroid disease are discussed.
Thyroglobulin (Tg),2 the molecular site of thyroid hormone
formation, is a large homodimeric glycoprotein with an Mr of
660,000. It is also a major antigen, involved in the pathogenesis
of thyroid autoimmunity. In fact, experimental autoimmune
thyroiditis (EAT) can be induced in genetically susceptiblemice
by immunization with human thyroglobulin (hTg) in complete
adjuvant, and autoantibodies to hTg are found in the blood of
humans affected with autoimmune thyroid disease (AITD),
even though their pathogenic significance is unclear (1). Several
post-translational modifications contribute to the molecular
microheterogeneity of hTg, including iodination, glycosylation,
phosphorylation, and sulfation (reviewed in Ref. 2). Iodine
addition and hormone formation at specific sites have themost
obvious implications for thyroid function, but the effects of
glycosylation on the hormone-forming efficiency at specific
sites and on the antigenicity of Tg have also been documented
(3, 4). hTg is modified with the addition of several oligosaccha-
ride units of different kinds, among which the N-linked type A
(high-mannose) and type B (complex) units have been charac-
terized best as to their composition and localization (5–7). Type
C units are linked to serine and threonine by O-glycosidic
bonds and contain D-galactosamine (5). AnotherO-linked type
D oligosaccharide unit was described, whichwas composed of a
repeating D-glucuronic acid-N-acetyl-D-galactosamine sulfate
disaccharide attached to the polypeptide chain through a
D-galactosyl-D-xylosyl-serine linkage region (8). Further study
* This work was supported by PRIN 2004 Grant 2004062075 from the Minis-
tero dell’Istruzione, Universita` e Ricerca, Rome, Italy (to F. G.). The costs of
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accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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supplemental Figs. 1 and 2 and Tables 1 and 2.
1 To whom correspondence should be addressed. Tel.: 39-0874-404852; Fax:
39-0874-404778; E-mail: gentilefabrizio@unimol.it.
2 The abbreviations used are: Tg, thyroglobulin; AITD, autoimmune thyroid
disease; APC, antigen-presenting cell; DMTCC, 3,3-diethyl-9-methyl-
4,5,4,5-dibenzothiacarbocyanine; EAT, experimental autoimmune thy-
roiditis; GAG, glycosaminoglycan; h8-deCSTR, peptide h8-CSTR digested
with chondroitinase ABC; hTg, human thyroglobulin; hTg-CS, type D
(chondroitin 6-sulfate) oligosaccharide unit-containing hTg; hTg-CS0, type
D (chondroitin 6-sulfate) oligosaccharide unit-devoid hTg; hTg-CSgp,
chondroitin 6-sulfate-containing glycopeptide 2726–2734 of hTg; Ii,
invariant chain; Ii-CS, chondroitin sulfate-containing invariant chain; LPO,
lactoperoxidase; MMI, 2-mercapto-1-methylimidazole; PVDF, polyvinyli-
denedifluoride;Q-IEC, ion-exchange chromatographyon trimethylamino-
substituted Q-Sepharose; T3, 3,5,5-triiodothyronine; T4, 3,5,3,5-tet-
raiodothyronine (thyroxine); TAO, thyroid-associated ophthalmopathy;
TPO, thyroid peroxidase; ES-MS, electrospray mass spectrometry; Tricine,
N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; HPLC, high pressure
liquid chromatography; TSH, thyrotropin.
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indicated that the repeating disaccharides were of the chon-
droitin 6-sulfate type (9, 10). However, the number and local-
ization of type D oligosaccharide units in hTg were not
determined.
A number of studies have documented the influence of oli-
gosaccharide chains in the processing and/or presentation of
glycoproteic antigens by antigen-presenting cells (APCs) (11–
16), and the involvement of chondroitin 6-sulfate oligosaccha-
ride chains in the modulation of cellular immune responses
(17–20). Prompted by these observations, we began to deter-
mine in detail the number and localization of chondroitin
6-sulfate oligosaccharide unit(s) in hTg as a basis for further
studies on their influence on the immunopathogenicity of hTg in
a murine model of EAT. We found that the addition of chon-
droitin 6-sulfate unit(s) is a major source of molecular microhet-
erogeneity of hTg. In dozens of hTgpreparations examined, it was
regularly found in a percentage of hTg molecules varying from
32.0 to71.6%of total.Moreover,wedetermined that a single chon-
droitin 6-sulfate unit per hTg polypeptide chain is linked to
Ser2730. We also observed changes in the hormone-forming effi-
ciency of hTg and in the proteolytic accessibility of the extreme
carboxyl-terminal region of hTg, associated with the presence of
the chondroitin 6-sulfate oligosaccharide chain. The former
observation contributes to delineate a general mechanism, by
which modifications in the composition and number ofN-linked
andO-linked oligosaccharide units determine changes in the hor-
mone-forming efficiency of the main hormonogenic domains at
both hTg extremities, whereas the latter finding supports the
potential role of the chondroitin 6-sulfate oligosaccharide unit in
modifying the susceptibility of hTg to processing byAPCs and the
repertoire of hTg epitopes thus generated.
EXPERIMENTAL PROCEDURES
Materials—Thermolysin from Bacillus thermoproteolyticus
rokko (EC 3.4.24.4), L-1-tosylamide-2-phenylethylchloromethyl-
treated trypsin from bovine pancreas (EC 3.4.21.4), endoprotein-
aseGlu-C from Staphylococcus aureus (EC 3.4.21.19), lactoperox-
idase (LPO) from bovine milk (EC 1.11.1.7), and glucose oxidase
from Aspergillus niger (EC 1.1.3.4) were purchased from Sigma.
Protease-free chondroitinase ABC from Proteus vulgaris (EC
4.2.2.4)was fromRocheAppliedScience.AminopeptidaseMfrom
porcine kidney (EC 3.4.11.2) and Pronase from Streptomyces gri-
seus were from Calbiochem. Sephacryl S-300 HR, HiTrapTM
Q-SepharoseHP,DEAE-SepharoseFastFlow, andSephadexG-50
fine were obtained from GE Healthcare. Bio-Gel P-2 and electro-
phoresis products were from Bio-Rad. Immobilon P membranes
and Centriprep 30 concentrators were from Millipore
(Vimodrone, Italy). HPLC-grade solvents were from Carlo
Erba (Milan, Italy). BCA protein assay reagent was from
Pierce. 3,3-Diethyl-9-methyl-4,5,4,5-dibenzothiacarbocya-
nine (DMTCC, Stains AllTM) was from ICN Biomedicals
(Milan, Italy). Solid-phase radioimmunoassay kits for total
3,5,5-triiodothyronine (T3) and 3,5,3,5-tetraiodothyronine
(thyroxine, T4) were from Diagnostic Products Corp. (Los
Angeles, CA). Marker kit MW-SDS-17S and other analytical
grade chemicals were from Sigma.
Purification of hTg—hTg was prepared as described (21)
from informed euthyroid patients hemilaryngectomized for
non-thyroidal disease and patients undergoing thyroidectomy
for nonfamilial, simple, ormultinodular goiter. Protein concen-
tration was assayed bymeasuring the optical absorbance at 280
nm, using an extinction coefficient of 10 cm1 for a 1% solution.
Iodine content was assayed as described, using L-thyroxine as
the standard (22).
Ion-exchange Chromatography of hTg on HiTrapTM Q-Sepha-
rose HP (Q-IEC)—hTgmolecules containing type D (chondroitin
6-sulfate) oligosaccharide units (hTg-CS) were separated from
residual hTg molecules, devoid of type D units (hTg-CS0), by
ion-exchange chromatography on trimethylamino-substituted
Q-Sepharose (Q-IEC) using 5-ml HiTrapTM Q-Sepharose HP
columns, equilibrated in 0.025 M Tris/HCl, pH 7.4 (buffer A).
Up to 20 mg of hTg in buffer A, plus 0.05 M NaCl, were applied
to a column. After washingwith buffer A, a linear gradient from
0 to 100% of buffer B (1.2 M NaCl in buffer A) was developed in
24 min at the flow rate of 2.5 ml/min. One-ml fractions were
analyzed or stored at80 °C until use.
Compositional Analysis of Q-IEC Fractions of hTg—D-Glucu-
ronic acidwas assayed inQ-IEC fractions by themeta-hydroxy-
biphenyl method (23), using the same compound (0–5 g) as
the standard. Duplicate samples of 30–500 g of hTg were
dialyzed against 0.01 M NH4HCO3, dried in centrifugal evapo-
rator, and redissolved in 0.2ml of double-distilledH2O in boro-
silicate Pyrex tubes. Samples were processed by the addition of
1.2ml of 0.0125 MNa2B4O710H2O inH2SO4 and, after heating
in boiling water bath for 5 min and cooling on ice, 0.02 ml of
0.15% meta-hydroxybiphenyl in 0.5% NaOH, after which the
optical absorbance at 520 nmwas read. Correction for aspecific
color development was provided by a replicate set of samples,
which were treated identically, with the exclusion of meta-hy-
droxybiphenyl in the 0.5% NaOH reagent. Total neutral hex-
oses were assayed in duplicate samples of 20–300 g of hTg by
the anthrone method (24), using D-galactose (0–20 g) as the
standard. Sialic acid was assayed in duplicate samples of
40–500g of hTg by the thiobarbituric acidmethod (25), using
N-acetylneuraminic acid (0–15g) as the standard. Iodine was
assayed in duplicate samples of 30–200 g of hTg, using the
method cited (22).
Enzymatic in Vitro Iodination of hTg and Analysis of the
Iodine, T3, and T4 Content—hTg from goiters, with an iodine
content not exceeding 0.09% on a weight basis, was iodinated
enzymatically in vitro. Bulk iodination of 20 mg of unfraction-
ated hTg, at the concentration of 0.45 g/liter, was performed in
0.02 M imidazole/HCl, pH 7.0, using 2 g/ml of LPO from
bovinemilk, 4 105 M potassium iodide, 1 103 M D-glucose,
and 0.19 g/ml glucose oxidase from A. niger. Iodination was
stopped with 0.05 M 2-mercapto-1-methylimidazole (MMI).
Comparative iodination of unfractionated hTg and of hTg-CS0
and hTg-CS subfractions of the same hTg preparation was per-
formed with 0.65 mg of each protein, under identical conditions,
except that7.5105Mpotassiumiodide, and0.21g/mlglucose
oxidasewereused.Aliquotsof 0.1mgofhTgwerewithdrawn at 5,
15, 30, 50, 70, and 90 min, supplemented with MMI, dialyzed
against 0.01 M NH4HCO3, 5  103 M NaCl, and assayed in
duplicate for protein content, using the BCA protein assay rea-
gent and bovine serum albumin as the standard, and for iodine
content, as already described. For the assay of T3 and T4, 10–15
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g of hTg were hydrolyzed at 37 °C with Pronase, at the
enzyme/substrate weight ratio of 1:1, in 0.2 ml of 0.1 M Tris/
HCl, 0.05 MMMI, pH 8.0, to which 15l of toluenewere added.
After 24 h, aminopeptidase M was added, at the enzyme/sub-
strate weight ratio of 1:10, and digestion was prolonged for 24 h
at 37 °C, after which T3 and T4 were measured by solid-phase
radioimmunoassays in antibody-coated tubes (26). In both
assays, 125I-labeled T3 or T4 competed with the respective hor-
mone in the test samples for antibody sites. After the tubeswere
decanted and radioactivity was measured, the T3 or T4 concen-
tration was obtained by interpolation from a calibration curve.
Limited Proteolysis of hTg—hTg, at the concentration of 1
g/liter in 0.05 MTris/HCl, 0.1 MNaCl, pH 7.4, was digestedwith
thermolysin, at the enzyme/substrate weight ratio of 1:50, at
30 °C for 80 min, or with L-1-tosylamide-2-phenylethylchlo-
romethyl-treated trypsin (henceforth referred to as trypsin), at
the enzyme/substrate weight ratio of 1:100, at 30 °C for 20 or 40
min. Proteolytic digestion was stopped with 3  105 M anti-
pain, 2 106 M aprotinin, 5 104 M benzamidine, 4 105
M leupeptin, 1  104 M N-p-tosyl-L-lysine chloromethyl
ketone, 2 105 M phenylmethylsulfonyl fluoride, 5 103 M
EDTA and, in the case of trypsin, soybean trypsin inhibitor, at
the inhibitor/enzyme weight ratio of 3:1. Thereafter, concen-
trated SDS-PAGE sample buffer was added to a final concen-
tration of 0.01 M Tris/HCl, pH 6.8, 1% SDS, 5% 2-mercaptoeth-
anol (v/v), 1.36 M glycerol, 0.0025% bromphenol blue, and the
samples were heated in a boiling water bath for 1.5 min and
immediately subjected to SDS-PAGE.
Enzymatic Digestion of Chondroitin 6-Sulfate Oligosaccha-
ride Units of hTg, hTg Subfractions, and hTg Proteolytic Frag-
ments with Chondroitinase ABC—hTg, or its proteolytic frag-
ments in 0.1 M NaCl, 0.05 M Tris/HCl, pH 7.4, were
supplemented with equal volumes of 0.1 M sodium acetate,
0.1 M Tris/HCl, pH 8.0. Pooled fractions from the Q2 peak of
the Q-IEC of hTg were dialyzed against the same buffer. All
samples were supplemented with 200 milliunits/ml of chon-
droitinase ABC from P. vulgaris, which degrades chondroitin
4-sulfate and 6-sulfate oligosaccharide chains into sulfated dis-
accharides by hydrolyzing the -(134)-glycosidic bonds
between N-acetyl-D-galactosamine 4- and 6-sulfate and D-glu-
curonic acid in the repeating disaccharide units. The protease
inhibitors already indicatedwith regard to limitedproteolysiswere
added, when not already present, and the samples were incubated
at 37 °C for 4h. Samples tobe analyzedbySDS-PAGEwere imme-
diately precipitated inmethanol/chloroform/water (27), although
those tobeused for enzymatic iodination in vitroor limited tryptic
digestion, following chondroitinase ABC digestion, were sub-
jected toQ rechromatography, as already described, concentrated
inCentriprep30concentrators, anddialyzed against the appropri-
ate buffer.
Separation and Identification of the Products of Limited Prote-
olysis of hTg—Analytical PAGEof thedigestionproducts of hTg in
Tris/glycine/SDS was performed using 4–17% total acrylamide,
2.7%N,N-methylenebisacrylamide gradient gels.Molecularmass
standards (Bio-Rad) were as follows: myosin (205,000 Da), -ga-
lactosidase (116,000 Da), phosphorylase b (94,000 Da), bovine
serum albumin (68,000 Da), ovalbumin (45,000 Da), carbonic
anhydrase (30,000Da), and soybean trypsin inhibitor (20,000Da).
Tworeplicas of eachgelwereprepared.Onewas stainedwith0.1%
Coomassie Brilliant Blue R-250 in 25% (v/v) 2-propanol, 10% (v/v)
acetic acid and destained in 25% (v/v) methanol, 10% acetic acid.
The other one was fixed in 25% 2-propanol, 10% acetic acid, thor-
oughly rinsed in double-distilled H2O, stained with 0.005%
DMTCC in 50% formamide for 48 h, and finally destained in 5%
(v/v) glycerol in tap water (28). Bands were identified on the basis
of their mobilities, according to the detailed characterization of
their NH2-terminal peptide sequences provided in a previous
study (21). Proteolytic fragments to be identified exnovowere sep-
aratedby reducingornonreducingSDS-PAGEin4–17%acrylam-
ide gradient gels and transferred to polyvinylidene difluoride
(PVDF) membranes (Immobilon P, Millipore) by semi-dry blot-
ting in 0.025 M Tris, 0.01 M glycine, at the constant current of 0.8
mA/cm2 for 1 h.Membraneswere rinsed in double-distilledH2O,
stained with 0.1% Coomassie Brilliant Blue R-250 in 50% metha-
nol, and destained in 50% methanol, 10% acetic acid. Bands were
subjected to NH2-terminal peptide sequencing at the Molecular
Structure Facility, University of California, Davis. Peptide
sequences were aligned with the cDNA-derived sequence of hTg
(29).
Isolation and Sequencing of Glycopeptide hTg-CSgp—Forty
sevenmgof hTg-CSwere denatured and reduced in 15ml of 0.3
M Tris/HCl, pH 8.0, 6.0 M guanidine/HCl, 1  103 M EDTA,
0.01 M dithiothreitol at 37 °C for 2 h. The reduced protein was
carboxymethylated with a 5-fold molar excess of iodoacet-
amide, with respect to total –SH groups, at room temperature
for 30min in the dark.Alkylationwas stoppedwith excess dithi-
othreitol. The sample was dialyzed against 0.05 M sodiumphos-
phate, pH 7.8, and digested with endoproteinase Glu-C (prote-
ase V8) from S. aureus at the enzyme/substrate weight ratio of
1:100 at 37 °C for 18 h. The sample was adjusted with concen-
trated solutions to 0.025 MTris/HCl, 0.1 MNaCl, 2.0 M urea, pH
7.4 (buffer C), and loaded onto a 5-ml HiTrapTM Q-Sepharose
HP column equilibrated in the same buffer. After washing with
buffer C, a gradient was started from 0 to 100% of buffer D (1.2
MNaCl in buffer C) in 55min, followed by 100% buffer D for 10
min at the flow rate of 1 ml/min. One-ml fractions were moni-
tored for the optical absorbance at 280 nm and D-glucuronic
acid content. A single D-glucuronic acid-containing peak was
subjected to size-exclusion chromatography on a 1.5 100-cm
column of Bio-Gel P-2 in 0.01 M NH4HCO3. A D-glucuronic
acid-containing peak, eluted in the void volume, was lyophilized
and further purified by gel chromatography on a 0.5  40-cm
columnof SephadexG-50 fine in 0.01 MNH4HCO3.One-ml frac-
tions were monitored for peptide content, by measuring the opti-
cal absorbance at 220 nm, and D-glucuronic acid content, and a
single peptide- and D-glucuronic acid-containing peak was lyoph-
ilized. A solubilized aliquot was subjected to NH2-terminal pep-
tide microsequencing. Purity was checked by PAGE in Tris/
Tricine/SDS in a 16.5% total acrylamide, 6% N,N-methylene-
bisacrylamide gel, containing 6.0 M urea (30). Molecular mass
standards (marker kit MW-SDS-17S, Sigma) were as follows:
myoglobin fragments 1–153 (16,950 Da), 1–131 (14,440 Da),
56–153 (10,600 Da), 56–131 (8,160 Da), 1–55 (6,210 Da), gluca-
gon (3,480 Da), and myoglobin fragment 132–153 (2,510 Da).
SDS-PAGEwas followed by semi-dry transfer to Immobilon P, as
Chondroitin 6-Sulfate Chain of Human Thyroglobulin
22202 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281•NUMBER 31•AUGUST 4, 2006
 at UNIVERSITA DI NAPO
LI on O
ctober 7, 2008 
w
w
w
.jbc.org
D
ow
nloaded from
 
described above, for 25 min. The membrane was stained with
DMTCC in 50% formamide and destained in tap water (28).
Purification of Carboxyl-terminal Tryptic Fragments of hTg
by HPLC—The fragments obtained from the limited digestion
of 20 mg of goiter hTg (0.03% of iodine on a weight basis) with
trypsin for 20 min, under the conditions described above, were
freed from trypsin immediately after digestion by filtration
through a 10-ml column ofDEAE-Sepharose Fast Flow in 0.025
M Tris/HCl, pH 7.2. hTg fragments were eluted with 0.15 M
NaCl in 0.025 M Tris/HCl, pH 7.2, and desalted by gel filtration
on a 1.5  100-cm column of Bio-Gel P-2, equilibrated with
0.01 MNH4HCO3.One-mg aliquots of the fragments were frac-
tionated by reverse-phase HPLC with a Vydac C-4 column
(250 10 mm, 5 m) equilibrated in 0.1% (v/v) trifluoroacetic
acid in H2O (solvent A) and containing 2% of 0.07% trifluoro-
acetic acid in acetonitrile (solvent B). After 2 min at 35% of
solvent B, the fragments were eluted with a two-step linear gra-
dient from 35 to 46% of solvent B over 35 min and from 46 to
55.5% over the following 35 min. The flow rate was 1 ml/min.
Fractionswere analyzed by SDS-PAGE in 4–17% total acrylam-
ide gradient gels under reducing and nonreducing conditions.
Corresponding peaks from repeated runs were pooled for fur-
ther mass spectrometric analysis.
Characterization of Carboxyl-terminal Tryptic Fragments of
hTg by Electrospray Mass Spectrometry—ES-MS of peptide
h4bisTR were recorded on a Q-TOF Ultima hybrid mass spec-
trometer (Waters), equipped with an electrospray ion source
and operating in positive ion mode. A nanoflow high pressure
pump system model CapLC (Waters) was used to deliver a
1-l/min flow rate of 10% acetonitrile to the mass spectrome-
ter. The spectra were scanned at the speed of 10 s/scan. The
source conditions were the following: capillary voltage, 3000 V;
cone voltage, 100 V; extractor, 0 V; RF lens, 60. Raw data were
processed using the MassLynx 3.5 software. Mass calibration
was carried out using themultiple charged ions from a separate
introduction of horse heartmyoglobin (averagemolecularmass
of 16,950.5 Da). The quantitative analysis was performed by
integration of the multiple charged ions of the single species.
Molecular masses are reported as average values. Themass sig-
nals recordedwere associatedwith the corresponding peptides,
on the basis of the expected molecular masses, using the Biol-
ynx software (Waters).
RESULTS
ARelevant Fraction of hTg Is RegularlyComposed of hTgMol-
ecules Provided with Type D (Chondroitin 6-Sulfate) Oligosac-
charide Units—Type D (chondroitin 6-sulfate) oligosaccharide
unit-containing hTg molecules were separated from residual
hTg molecules by using ion-exchange chromatography on tri-
methylamino-substituted HiTrapTM Q-Sepharose HP (GE
Healthcare). The Q-IEC of 40 hTg preparations, mostly from
nonfamilial, simple, and multinodular goiters but also from
normal thyroids, using a NaCl gradient from 0 to 1.2 mol/liter
in 0.05 M Tris/HCl, pH 7.4, regularly resulted in the elution of
two peaks (henceforth referred to as peaks Q1 and Q2, in elu-
tion order) at NaCl concentrations of 0.45  0.01 and 0.84 
0.03 M, respectively (Fig. 1). In 18 chromatograms, the area
under the Q2 peak varied from 32 to 71.6% of total (mean,
52.8%; median, 51.7%), with no apparent relation with the
iodine content (Table 1). The hTg subpopulations thus sepa-
rated were stable, and separation was satisfactory for practical
purposes, as shown by pooling and rechromatography of the
two peaks (Fig. 2, panel A). We traced chondroitin 6-sulfate
oligosaccharide units in hTg fractions by assaying their D-glu-
curonic acid content, using a meta-hydroxybiphenyl-based
FIGURE 1. Fractionation by ion-exchange chromatography on HiTrapTM
Q-SepharoseHP (Q-IEC) of selectedhTgpreparations and compositional
analysis of the resulting fractions. Twenty-mg aliquots of hTgpreparations
O. (panel A), Ma. (panel B), and D. (panel C) in 0.025 M Tris/HCl, 0.05 M NaCl, pH
7.4, were loaded onto a 5-ml HiTrapTM Q-Sepharose HP column, equilibrated
with 0.025 M Tris/HCl, pH 7.4 (buffer A). After washing with buffer A, a linear
gradient from 0 to 100% of buffer B (1.2 M NaCl in buffer A), in 24 min, at the
flow rate of 2.5ml/min,was applied (the dashed-dotted line indicates theNaCl
concentration at the column head, with reference to the left y axis; dead
volumewas 6.0ml). One-ml fractions weremonitored for protein content, by
measuring the optical absorbance at 280 nm (continuous line), and carbohy-
drate content. The symbols used are as follows: neutral hexoses content, in
mmol/liter (hatched line); D-glucuronic acid (GlcUA) content, in mol/liter
(dashed line), andmol/hTgmol (F); N-acetylneuraminic acid (NANA) content,
in mol/hTg mol (E). The analysis of one fraction every other two by PAGE
under native conditions, in a 4–9% total acrylamide gradient gel stainedwith
Coomassie Brilliant Blue R-250, is shown on top of panels A and B.
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method (23). D-Glucuronic acid was almost exclusively
restricted in the Q2 peak, which coincided with a fraction of
hTg, marked by the presence of D-glucuronic acid-containing
type D (chondroitin 6-sulfate) oligosaccharide units (hence-
forth referred to as hTg-CS) (Fig. 1). Negligible amounts of
D-glucuronic acid in the Q1 peak possibly reflected the pres-
ence of hTgmolecules with very short, nascent typeD oligosac-
charide chains. The neutral hexose content remained constant
or increased slightly along the elution profile of the chromato-
grams, while the sialic acid content showed no change or only
moderate changes in either sense (Fig. 1 and Table 1). Instead,
the number of moles of D-glucuronic acid per mol of hTg reg-
ularly exhibited a linear increase across theQ2peak, ranging from
a minimum of about 3 to a maximum of 13.2 mol in the hTg
preparationwith the lowest fraction of hTg-CS, and of 24.0mol in
some hTg-CS-rich goiter hTg preparations (Table 1). In particu-
lar, preparationsMi. andMi. N. had elution profiles (preparations
are named using last initial(s) of patients), in which a shoulder in
the trailingedgeof theQ2peak indicated thepresenceof a second-
ary component, eluting at 0.96 M NaCl (Fig. 2, panel B). We
hypothesized that the complexity and extended span of D-glu-
curonic acid content of these Q2 peaks might reflect the coex-
istence of heterodimeric hTg-CS, with a single chondroitin
6-sulfate-bearing subunit, and homodimeric hTg-CS. To prove
this, pooled fractions of theQ2 peak from theQ-IEC of hTgMi.
N. were dissociated in 0.04 M Tris/HCl, 2.5 M urea, pH 9.0, at
20 °C overnight, as described previously (31), and subjected
again to Q-IEC, using a NaCl gradient from 0 to 1.2 mol/liter in
2.5 M urea, 0.055 M Tris/HCl, pH 7.4. As shown in Fig. 2, panel
B, the hTg monomers produced by the dissociation of hTg-CS
in urea were separated again into peaks Q1 and Q2, eluting at
NaCl concentrations of 0.44 and 0.86 mol/liter, respectively.
Once again, D-glucuronic acid was restricted in the Q2 peak,
and its concentration showed a linear increase from 3.2 to 14.8
mol/hTg mol across the peak span, as opposed to the increase
from 3.6 to 24.0 mol/mol of undissociated hTg-CS (Table 1).
TheQ2 peak of dissociated hTg-CSwas superimposed onto the
leading component of the Q2 peak of native hTg-CS, with no
secondary shoulder at the trailing edge. The Q2/Q1 ratio in
hTg-CS dissociated in urea was 72.7 versus 27.3%. These data
indicate that the hTg-CS fraction of hTg Mi. N. included both
an earlier eluting subfraction of heterodimers, composed of
nonchondroitinated (27.3%) and chondroitinated (27.3%)
monomers in the 1:1 ratio, and a later eluting homodimeric
subfraction, composed only of chondroitinated subunits,
and representing the remaining 45.4% of hTg-CS. Thus,
hTg-CS was microheterogeneous, both because of the vari-
able number of repeating disaccharide units per chondroitin
6-sulfate chain, which is typical of glycosaminoglycans
(GAGs) (32), and because of the coexistence of het-
erodimeric and homodimeric hTg-CS molecules in hTg-CS-
rich goiter hTg preparations. When the pooled fractions of
the Q2 peak from the Q-IEC of hTg preparation Ca. were
digested with chondroitinase ABC and subjected to Q
rechromatography, they eluted in a peak superimposed onto
the Q1 peak of the initial Q-IEC of native hTg (Fig. 2, panel
C). Fig. 1, panels A and B, also shows the native PAGE of the
Q-IEC fractions of hTg preparations O. and Ma., evidencing
the anodal shift, going from the Q1 to the Q2 peak, because
of the added negative charge of D-glucuronic acid residues
and sulfate groups of the chondroitin 6-sulfate unit(s).
hTg-CS Has a Higher Efficiency of T3 and T4 Formation than
hTg-CS0 and Enhances the Overall Hormonogenic Efficiency of
hTg—We investigated the possible influence of the chondroitin
6-sulfate oligosaccharide unit(s) on the hormonogenic function
of hTg-CS, in comparison with chondroitin 6-sulfate-devoid
hTg (henceforth referred to as hTg-CS0), and unfractionated
hTg. Iodination of Tg at the apical pole of thyroid follicular cells
occurs by the action of thyroid peroxidase (TPO) (reviewed in
Ref. 2). Lactoperoxidase (LPO) is a common alternative for
TPO in reconstituted systems of iodination and coupling
in vitro. TPO and LPO are equally effective in the selective iodi-
nation of a subset of tyrosyl residues, which are able to undergo
coupling to form T3 and T4. TPO and LPO also catalyze the
coupling of iodotyrosines with similar efficiencies at pH 7.4,
even though LPO is significantly less efficient at lower pH (33).
Iodine-poor unfractionated hTg, hTg-CS0, and hTg-CS from
nonfamilial goiters (with no more than 0.09% of iodine, on a
weight basis) were iodinated enzymatically in vitro by using 2
g/ml bovine LPO, 7.5 105 M potassium iodide, 0.21 g/ml
glucose oxidase fromA. niger, and 1 103 M D-glucose over 90
min at 25 °C (34). Fig. 3 shows themeans S.E. of the amounts
of iodine incorporated into hTg, expressed as percent of hTg on
a weight basis, and of the levels of T3 and T4 formed as a func-
TABLE 1
Compositional analysis of selected hTg preparations subjected to Q-IEC on HiTrapTM Q-Sepharose HP
hTg preparationa hTg-CS,% of hTg
D-Glucuronic acid in Q2 peak Total neutral hexoses
range,d % (w/w)
N-Acetylneuraminic acid
range,d mol/hTg mol
Iodine, % of
hTg (w/w)mol/liter b mol/hTg molb Range,c mol/hTg mol
O. 65.8 11.8 10.0 3.8–14.3 10.7–10.2 18.0–19.8 0.50
Ma. 38.9 3.9 7.0 3.9–13.2 8.0–10.4 15.1–18.2 0.12
T. 48.3 7.2 7.7 3.7–14.0 4.9–6.1 9.8–9.9 0.02
Ce. 51.2 7.5 7.3 2.8–14.2 7.0–8.5 0.09
D. 66.3 14.8 11.7 3.9–15.7 4.4–5.4 16.0–14.0 0.16
Mi. 71.6 20.9 15.6 3.1–23.8 0.16
Mi. N.e 63.1 16.8 12.0 3.6–24.0 0.08
Mi. N. Q2 peak in urea f 72.7 20.2 13.6 3.2–14.8
a hTg preparations were named after the patients (using the last initial(s)). PreparationO. was from a euthyroid individual, hemilaryngectomized for a non-thyroidal disease; the
other preparations were from nonfamilial, simple, or multinodular goiters.
b Values were measured in the fractions with the maximal protein concentration in the Q2 peak.
c Data indicate the D-glucuronic acid concentration range across the span of the Q2 peak, starting from the valley between the Q1 and the Q2 peaks.
d Data indicate the concentration range across the entire span of the Q-IEC, from the leading edge of the Q1 peak to the trailing edge of the Q2 peak.
e Preparation obtained from a large 2 3-cm colloid nodule, surrounded by apparently normal thyroid tissue, from patient Mi.
f Pooled fractions of the Q2 peak from the Q-IEC of hTg preparation Mi. N. were dissociated in 0.04 M Tris/HCl, 2.5 M urea, pH 9.0, for 18 h at 20 °C, as reported (31), and then
subjected again to Q-IEC, using a gradient from 0 to 1.2 M NaCl in 0.055 M Tris/HCl, 2.5 M urea, pH 7.4.
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tion of iodine bound during four experiments of time course of
iodination in vitro. Each experiment was performed using
unfractionated hTg, together with hTg-CS0 and hTg-CS sub-
fractions deriving from the same iodine-poor hTg preparation.
The average fraction of hTg-CS in the hTg preparations used
was 58.1%. Similar amounts of iodine were incorporated at pla-
teau in hTg and hTg-CS, and slightly higher amounts in hTg-
CS0 (Fig. 3, panel A). However, the number of T3 millimoles
(panel B) and T4 moles (panel C) synthesized per mol of
hTg-CS were in the ratios of 1.70 and 1.34, respectively, with
those synthesized per mol of hTg-CS0. Instead, hTg and
hTg-CS did not differ, as for the efficiency of formation of T3
and T4. These data indicated that hTg-CS had a higher effi-
ciency of T4 and, especially, T3 formation than hTg-CS0 and
that the entire population of unfractionated hTg molecules
benefited from this property of hTg-CS.A rationale for thismay
be that chondroitin 6-sulfate chains exerted an influence not
only on the hTg-CS molecules they were linked to but also on
the hTg-CS0 molecules they interacted with or on the peroxi-
dase. If so, one would not expect to see differences of hormone
yields between hTg-CS and hTg-CS0 when these were iodi-
nated altogether in the pool of unfractionated hTg. Such a pre-
diction was verified by the lack of significant variations in the
amounts of T3 and T4 formed, between the Q-IEC fractions of
hTg preparation O., physiologically iodinated in vivo (Fig. 4).
Previous digestion of hTg-CS with 200 milliunits/ml of chon-
droitinase ABC from P. vulgaris, at pH 8.0 and 37 °C for 4 h, was
not associated with reductions of the T3 and T4 yields, with
respect to native hTg-CS, and of the differences of hormone-
forming efficiency between hTg-CS and hTg-CS0.
Chondroitin 6-Sulfate Oligosaccharide Unit(s) of hTg-CS
Are Restricted in the Carboxyl-terminal Region, Downstream
Thr2514—We were able to differentiate hTg-CS from hTg-CS0
in SDS-polyacrylamide gels by staining them with DMTCC
(StainsAllTM, ICN). This dyewas reported to stainGAGsmeta-
chromatically and, in particular, chondroitin sulfate purple,
while staining proteins red (35). In fact, fractions in the Q1
(hTg-CS0) peak were stained pinkish red with DMTCC, and
those in the Q2 (hTg-CS) peak were stained purple. Side-by-
side comparison of the two peak fractions also revealed a subtle
cathodal shift in hTg-CS in the presence of SDS. Both meta-
chromasia and the mobility shift were abolished by digestion
with 200 milliunits/ml of chondroitinase ABC, at 37 °C for 4 h,
prior to SDS-PAGE (Fig. 5, panel A). To identify the chon-
droitin 6-sulfate-containing region(s) of hTg, the Q-IEC frac-
tions of hTg were subjected to limited digestion with thermo-
lysin and trypsin, using DMTCC as a probe. The proteolytic
fragments, separated by reducing SDS-PAGE, corresponded
exactly to those characterized previously byNH2-terminal pep-
tide sequencing (21) and were identified on the basis of their
mobilities. Fig. 5, panel B, shows the SDS-PAGE of the diges-
tion products of fractions 29, 40, 48, and 56 of hTg preparation
200 milliunits/ml of chondroitinase ABC from P. vulgaris for 4 h at 37 °C, and
finally subjected to Q rechromatography. The optical absorbance at 280 nm
of the fractions of the initial Q-IEC (continuous line) andof theQ rechromatog-
raphy of the Q2 peak digested with chondroitinase ABC (dotted line) was
monitored.
FIGURE 2. Fractionation by Q-IEC of selected hTg preparations, followed
byQ rechromatographyof thepeaksobtained therefrom,under various
conditions. Panel A, following the Q-IEC of 20 mg of hTg preparation I., as
described in the legend to Fig. 1, the fractions of the Q1 and Q2 peaks
obtained therefromwere pooled separately, with the exclusion of three frac-
tions between peaks. Each pool was dialyzed against buffer A and subjected
to Q rechromatography, under identical conditions as the initial Q-IEC. The
optical absorbance at 280 nm of the fractions of the initial Q-IEC (continuous
line) and of the Q rechromatography of the Q1 (dotted line) and Q2 peak
(dashed line) was monitored. Panel B, following the Q-IEC of 20 mg of hTg
preparationMi. N., the fractions of theQ2 peakwere pooled, dialyzed against
bufferA, dissociated in0.04MTris/HCl, 2.5Murea, pH9.0, at 20 °Covernight, as
reported (31), and subjected toQ rechromatographybyusingaNaCl gradient
from0 to 1.2mol/liter in 2.5 M urea, 0.055M Tris/HCl, pH 7.4. The symbols used
are as follows: optical absorbanceat 280nmof the fractionsof the initialQ-IEC
(continuous line) andof theQ rechromatographyof theQ2peakdissociated in
urea (dashed line); D-glucuronic acid (GlcUA) content, in mol/hTg mol, of the
fractions of the initial Q-IEC (F) and of the Q rechromatography of the Q2
peak dissociated in urea (E). Panel C, following the Q-IEC of 20 mg of hTg
preparation Ca., the fractions of the Q2 peak were pooled. An aliquot of 6mg
of thismaterial was taken to the volume of 1.5ml with Centriprep 30 concen-
trators, dialyzed against 0.1 M Tris, 0.1 M sodiumacetate, pH 8.0, digestedwith
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O. with thermolysin. Bands h2TL, h5TL, and h7TL exhibited
metachromasia and a cathodal shift, whose extentwas inversely
related with the fragment apparent mass, going from fraction
29 in the Q1 peak to fractions 48 and 56 in the Q2 peak. This is
in keeping with the notion that peptides with high negative net
charges bind lower than average amounts of SDS, and they
exhibit lower than average mobilities in SDS-PAGE (36). A
mixed patternwas apparent in fraction 40, in the valley between
the Q1 and Q2 peaks. Both changes were reverted by digestion
of the proteolytic fragments of fraction 48 with chondroitinase
ABC, prior to SDS-PAGE, although no changes were brought
about in fraction 29 (Fig. 5, panel C). Inspection of the flow
diagram of the limited proteolysis of hTg with thermolysin
revealed that fragments h2TL, h5TL, and h7TLwere all located at
the carboxyl-terminal side of hTg and shared the region down-
stream from Leu1832 (Fig. 6, panel A).
On the other hand, a diffuse band (h8-CSTR), with an average
apparent mass of 41,000 Da, appeared among the tryptic frag-
ments of hTg, going from fraction 29 to fraction 40. It was stained
purplewithDMTCC, butwas not apparent in the gel stainedwith
CoomassieBrilliantBlueR-250. Its intensityof stainingandappar-
ent relative mass increased going from fraction 40 to 56 (Fig. 5,
panelD), in keepingwith the increaseof D-glucuronic acid content
revealed by the analysis of the Q-IEC fractions across the Q2
peak (Fig. 1 and Table 1). Upon digestion of the tryptic frag-
ments of fraction 48 with chondroitinase ABC, band h8-CSTR
was replaced by a well focused band, corresponding to dechon-
droitinated h8-CSTR (h8-deCSTR), with an apparent mass of
36,000 Da, which was stained blue with Coomassie Brilliant
Blue R-250 and red with DMTCC. No changes were caused by
chondroitinase ABC in fraction 29 (Fig. 5, panel E). The forma-
tion of band h8-deCSTR was not prevented when the limited
digestion of hTg-CS with trypsin was preceded, rather than
followed, by digestion with chondroitinase ABC under identi-
cal conditions. Band h8-deCSTR was prepared by limited
tryptic digestion of 0.5 mg of hTg-CS, followed by chon-
droitinase ABC digestion, reducing SDS-PAGE and transfer
to PVDF. NH2-terminal peptide microsequencing of this
FIGURE 3. Enzymatic in vitro iodination and analysis of the hormone-
forming efficiency of hTg, hTg-CS0, and hTg-CS. Iodine- and hormone-
poor hTg (F) and its subfractions hTg-CS0 (f) and hTg-CS (E), prepared by
Q-IEC, at the concentrationof 0.45g/liter in 0.02M imidazole/HCl, pH7.0,were
iodinated enzymatically in vitro, using 2 g/ml of bovine LPO, 7.5 105 M
potassium iodide, 0.21g/ml of glucose oxidase fromA. niger and 1 103 M
D-glucose, over 90 min at 25 °C (34). Individual experiments were performed
usingunfractionatedhTg, hTg-CS0, andhTg-CS subfractionsderived from the
same iodine-poor hTgpreparation. The average percent content of hTg-CS in
the hTg preparations used was 58.1%. At the times indicated, aliquots were
removed, dialyzed against 0.01 M NH4HCO3, 0.005 M NaCl, and the iodine
content was assayed and expressed as percent of the protein on a weight
basis (panel A). After digestion with Pronase and aminopeptidase M, as
describedunder “Experimental Procedures,” T3 (panel B) andT4 (panel C )were
also assayed by radioimmunoassay. Points represent mean  S.E. values of
four experiments. For the sake of clarity, S.E. values are indicated only for
hTg-CS0 and hTg-CS.
FIGURE 4. Iodine and hormone content of the Q-IEC fractions of physio-
logically iodinated hTg preparation O., fromnormal thyroid tissue, con-
taining 0.50% iodine (w/w). The hTg preparationwas subjected toQ-IEC, as
described in the legend toFig. 1, and the fractionsobtainedwere analyzed for
their iodine (Œ), T3 (F), and T4 (E) content, as described under “Experimental
Procedures.” The continuous line indicates the optical absorbance at 280 nm,
forwhichmeasuring units are not indicated as theywere the same as in Fig. 1.
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band revealed a single sequence (TSSKTA), corresponding to
hTg residues 2514–2519 (29) (see supplemental Table 1). Nat-
urally, this was also the sequence of peptide h8-CSTR. The flow
diagram of limited proteolysis of hTg with trypsin shows the
carboxyl-terminal location of peptide h8-CSTR, in keeping with
the results obtained with thermolysin (Fig. 6, panel B). Because
theNH2-terminal sequence of peptide h8-deCSTRwas identical
with one of two sequences found previously in band h4TR (21),
we also determined the sequence of band h4TR prepared from
hTg-CS. As expected, two sequences were found, one starting
at residue 1 of hTg (h4TR) and the other one at residue 2514
(h4bisTR) (supplemental Table 1). Thus, of two peptides, both
starting at residue 2514, one (h8-CSTR) contained chondroitin
6-sulfate oligosaccharide units and the other (h4bisTR) did not.
Inspection of Fig. 5,panelD, reveals that the increase of staining
intensity of band h8-CSTR, going from fraction 40 to 56, was
paralleled by a decrease of intensity of band h4TR, in keeping
with the finding that heterodimeric hTg-CS, yielding peptides
h8-CSTR and h4bisTR, and homodimeric hTg-CS, yielding only
peptide h8-CSTR, coexisted in the late portion of the Q2 peak
(Fig. 2, panel B).
A Single Type D (Chondroitin 6-Sulfate) Oligosaccharide
Unit Is Linked to Ser2730 of hTg-CS—Forty sevenmg of hTg-CS
were reduced and carboxymethylated, as reported under
“Experimental Procedures,” and hydrolyzed with endoprotein-
ase Glu-C from S. aureus, at the enzyme/substrate weight ratio
of 1:100, in 0.05 M sodium phosphate buffer, pH 7.8, at 37 °C for
18 h. Digestion products were subjected to Q-IEC on a 5-ml
HiTrapTM Q-Sepharose HP column, using a gradient from 0.1
to 1.2 MNaCl in 0.025 MTris/HCl, 2.0 M urea, pH 7.4, in 55min,
at the flow rate of 1 ml/min. Most protein was discarded in the
flow-through, whereas a unique D-glucuronic acid-containing
peak, having negligible absorbance at 280 nm, was eluted late
in the gradient (supplemental Fig. 1, panel A). This peak was
subjected to size-exclusion chromatography on Bio-Gel P-2
(size-exclusion limit of 1800 relative mass units) in 0.01 M
NH4HCO3, which yielded a D-glucuronic acid-containing peak
in the void volume. Its further purification by size-exclusion
FIGURE 5. SDS-PAGE under reducing conditions of selected Q-IEC fractions of hTg preparation O., either as such or subjected to limited proteolysis
with thermolysin or trypsin and/or digestion with chondroitinase ABC. Panel A, top fractions of the Q1 peak (fraction 29) and Q2 peak (fraction 48),
analyzed before () and after () digestion with 200 milliunits/ml of chondroitinase ABC, in a 4–13% total acrylamide gradient gel stained with DMTCC. The
positions of chondroitinase ABC (ABC ) and carrier bovine serum albumin (BSA) are indicated. Panel B, digestion products of the fractions indicated with
thermolysin (TL), at the TL/hTg ratio of 1:50, pH 7.8, and at 30 °C for 80min, analyzed in replicate 4–17% total acrylamide gels, stainedwith Coomassie Brilliant
Blue R-250 (left) andDMTCC (right). Fragments aremarked at right in accordancewith Ref. 21. Fragments exhibiting cathodal shifts andmetachromasia, going
from the Q1 to the Q2 peak, are shown in purple. Panel C, further digestion with chondroitinase ABC of the products of proteolysis of fractions 29 and 48 with
thermolysin.PanelD, digestionproductsof the fractions indicatedwith trypsin (TR), at theTR/hTg ratioof 1:100, pH7.8, andat30 °C for 40min.Panel E, digestion
with chondroitinase ABC of the products of proteolysis of fractions 29 and 48 with trypsin. Dechondroitinated peptide h8-CSTR (h8-deCSTR) is circled. Relative
molecular mass standards (St), as detailed under “Experimental Procedures,” are marked at left of each gel.
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chromatography on Sephadex G-50 fine, in 0.01 M NH4HCO3,
monitored at 220 nm, is shown in supplemental Fig. 1, panel B.
Of the two peaks resolved, only one peak contained D-glucu-
ronic acid. NH2-terminal peptide microsequencing of this
material revealed a single, homogeneous nonapeptide with the
LTAGXGLRE sequence, corresponding to residues 2726–2734
of the cDNA-derived sequence of hTg (29), X being Ser2730
linkedwith the chondroitin 6-sulfate oligosaccharide unit (sup-
plemental Table 1). This glycopeptide will be henceforth
referred to as hTg-CSgp. The comparison between the
sequence around Ser2730 and a consensus for the recognition of
serine residues by UDP-D-xylose:proteoglycan core protein
-D-xylosyltransferase, deriving from the alignment of 51
chondroitin 6-sulfate attachment sites of 19 proteoglycan core
proteins (37), revealed a 90% concordance, provided that two
insertions of 3 and 2 residueswere allowed (Fig. 7). The purified
aliquot of hTg-CSgp contained 41.1 g of D-glucuronic acid
and 25.2g of protein. On the basis of theMr of 903, calculated
for the peptide moiety, this indicated an average content of 8.4
mol of D-glucuronic acid per mol of glycopeptide. Electro-
phoresis of 18g of hTg-CSgp in a 16.5% polyacrylamide gel in
Tris/Tricine/SDS, followed by transfer to a PVDF membrane
and staining with DMTCC, revealed a homogeneous, meta-
chromatic band with the diffuse migration, which is typical of
GAGs (17, 32), and an apparent molecular mass of 13,000–
20,000 Da, both indicating polydispersity (supplemental Fig. 1,
panel C). hTg-CSgp was labile upon freezing and thawing.
The Chondroitin 6-Sulfate Oligosaccharide Unit of hTg-CS
Protects Peptide Bond Lys2714–Gly2715 from Proteolysis—Next,
we sought an explanation for the difference between the appar-
ent relative molecular masses of peptides h8-deCSTR (36,000
Da) and h4bisTR (29,000 Da), by determining the carboxyl ter-
minus of the latter. In fact, only a minor part of the mass differ-
ence could be accounted for by the residual oligosaccharide
(GlcUA-Gal-Gal-Xyl), which was left in situ after chondroiti-
nase ABC digestion. Even though peptide h4bisTR comigrated
with h4TR, in reducing SDS-PAGE of the products of tryptic
digestion of hTg described above, previous observations indi-
cated that the homologous peptide b11TR of bovine Tg was free
of comigrating species under nonreducing conditions, because
it was the sole fragment not linked to other fragments by disul-
fide bonds (38). In fact, nonreducing SDS-PAGE of the tryptic
fragments of hTg yielded only two bands instead of several
bands seen with reduction (supplemental Fig. 2, panel B). NH2-
terminal microsequencing of band h4TR-NR, transferred onto
PVDF, revealed the same sequence as peptide h4bisTR, starting
at residue 2514, together with traces of a sequence starting at
residue 2518 (supplemental Table 1). Thus, the products of lim-
ited tryptic digestion of goiter hTg (with an iodine content of
0.03%, on a weight basis), at the enzyme/substrate weight ratio
of 1:100, at 30 °C for 20 min, were subjected to reverse-phase
HPLC in the absence of reduction, using a Vydac C-4 column
FIGURE 6. Flowdiagrams of the limited proteolysis of hTgwith thermoly-
sin (panel A) and trypsin (panel B) (21). Each bar represents a peptide, with
the peptide number above the bar, the apparent relative molecular mass
below at right, and the amino-terminal residue number below at left, accord-
ing to Ref. 29. Fragments of hTg-CS, which exhibited cathodal shifts and
metachromasia upon staining with DMTCC, with respect to their counter-
parts deriving fromhTg-CS0, are shown ingray. Their apparent relativemolec-
ular masses, both before and after digestion with chondroitinase ABC (ABC),
are indicated. Cross-hatching of bars h4TL and h2TR indicates that, under the
digestion conditions used, the corresponding peptides were not detected in
the gels shown in Fig. 5.
FIGURE 7.Diagrammatic representation of the localization and structure
of type D (chondroitin 6-sulfate) oligosaccharide unit of hTg. The
cDNA-deduced amino acid sequence of hTg, from residue 2710 to 2749, is
represented in the single-letter code (29). Black circles with white lettering
mark the sequence found for the purified glycopeptide hTg-CSgp (with the
proviso that Ser2730 appeared as a blank). A consensus sequence for the rec-
ognition of core protein serine residues by UDP-D-xylose:proteoglycan core
protein-D-xylosyltransferase (37) is alignedwith thehTg sequence, andcon-
cordances are indicated. A diagram of the chondroitin 6-sulfate oligosaccha-
ride unit attached to Ser2730 is shown (8–10). The number of repeating -D-
glucuronic acid-N-acetyl-D-galactosamine 6-sulfate disaccharide units per
chondroitin 6-sulfate chain found in the present study is indicated. The two
sites of tryptic cleavage between residues 2714–2715 and 2745–2746 found
in the present study and the preferential site of T3 formation at Tyr
2747 (29, 40,
41) are also marked.
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(250 10mm, 5m) and a gradient of acetonitrile in trifluoro-
acetic acid (supplemental Fig. 2, panel A). Nonreducing SDS-
PAGE of peak 2 revealed band h4TR-NR. Upon reduction, this
band exhibited the same relative apparent mass as peptide
h4bisTR (supplemental Fig. 2, panel B). The mass values associ-
ated with this band were determined by ES-MS (supplemental
Table 2) and defined a peptide having ragged amino- and car-
boxyl-terminal ends (residues 2512–2514 and 2713–2714,
respectively) and containing a high-mannose oligosaccharide
unit, composed of 2N-acetyl-D-glucosamine and 8 or 9 D-man-
nose residues, linked to Asn2563, as reported previously (7, 29,
39). Furthermore, the ES-MS analysis of HPLC peak 1 revealed
amass value corresponding to hTg peptide 2715–2745 (supple-
mental Table 2). Thus, peptide h4bisTR was truncated at
Lys2714, whereas peptide bond Lys2714–Gly2715 was protected
from proteolysis in peptide h8-CSTR, which extended through
Ser2730, with its bound chondroitin 6-sulfate unit. Another
tryptic site was located between Lys2745 and Thr2746 (Fig. 7).
DISCUSSION
The present study shows that type D (chondroitin 6-sulfate)
oligosaccharide units are amain source of molecular microhet-
erogeneity of hTg, being regularly found in a significant and
sometimes predominant fraction of it. We developed an IEC
method, which permitted us to separate chondroitin 6-sulfate-
containing hTg molecules (hTg-CS) from the residual hTg
molecules (hTg-CS0). By exploiting the changes of electro-
phoretic mobility and staining properties conferred upon the
products of limited proteolysis of hTg by chondroitin 6-sulfate
units, we first restricted the chondroitin 6-sulfate-containing
regions of hTg to a carboxyl-terminal peptide, starting at
Thr2514. The subsequent purification of a homogeneous, D-glu-
curonic acid-containing nonapeptide (hTg-CSgp), correspond-
ing to hTg residues 2726–2734, permitted us to establish
Ser2730 as the sole site of chondroitin 6-sulfate addition in hTg.
The surrounding sequence showedconcordancewith a consensus
sequence for the recognition of core protein serine residues by
UDP-D-xylose:proteoglycan core protein -D-xylosyltransferase,
with the exceptionof two insertions of three and two residues (Fig.
7), in keeping with the finding that recognition sequences of pro-
teins, which are not modified quantitatively with chondroitin sul-
fate, match the consensus less well than those of proteins that
are (37). The presence in hTg ofO-linked oligosaccharide units,
composed of 1 mol of D-xylose, 2 mol of D-galactose, 11 mol of
a D-glucuronic acid-N-acetyl-D-galactosamine disaccharide,
and up to 14 mol of sulfate per mol of serine was reported (8).
Based on numbers ofmoles of D-glucuronic acid permol of hTg
varying from 4.8 to 8.7 in different hTgs, it was suggested that
some hTg molecules might be devoid of type D units, although
somemight contain units of different sizes ormultiple units (8).
Subsequent studies showed that the repeating disaccharides
were of the chondroitin 6-sulfate type (9, 10). Our data show
that a relevant hTg fraction regularly contained a single chon-
droitin 6-sulfate unit per polypeptide chain, linked to Ser2730
and composed of a broadly varying number of repeating disac-
charide units. In some goiter hTg preparations with high con-
tents of hTg-CS, hTg-CSheterodimers, inwhich only onemon-
omer contained a chondroitin 6-sulfate chain, coexisted with
hTg-CS homodimers. In the monomers derived from the dis-
sociation of hTg-CS in urea, the net number of disaccharide
units per chondroitin 6-sulfate chain did not exceed 14.
We also show that hTg-CS had a higher efficiency of hor-
mone formation than hTg-CS0 and that the whole unfraction-
ated hTg benefited from this property. Thus, chondroitin 6-sul-
fate addition represents an ergonomic mechanism, by which
the post-translational modification of a fraction of molecules
influences the overall function of hTg. The greater advantage in
the formation of T3, with respect to T4, associated with the
chondroitin 6-sulfate unit, and the proximity of the attachment
site of the latter to the carboxyl terminus of hTg suggest that it
may influence hormonogenesis by affecting the function of the
site of preferential T3 formation at Tyr2747 (29, 40, 41). Normal
ranges of serum T4 concentration (64–142 nmol/liter) and T3
concentration (1.1–2.9 nmol/liter) have higher limits that
exceed the lower ones only by a factor of 2.2 and 2.6, respec-
tively (42), so that the increases in the rates of T4 and T3 forma-
tion in hTg-CS, in comparison with hTg-CS0, observed in the
present studymay be physiologically significant. The regulation
of the T4/T3 ratio in thyroid secretion is crucial formaintaining
physiological concentrations of active hormone (T3) in blood
and is finely tuned by multiple mechanisms, under the control
of TSH (2). The T4/T3 ratio is regulated first at the biosynthetic
level inTg and decreases in experimental animals givenTSH. In
rabbit and guinea pig Tg, TSH stimulates T3 formation at tyro-
sine 2747 and decreases T4 synthesis at tyrosine 5 (40). The
diminished T4 formation at the amino terminus of Tg is medi-
ated by the TSH-stimulated maturation of the N-linked oligo-
saccharide chain linked toAsn91, from the high-mannose to the
complex type (3). The data that we present contribute to delin-
eate a common mechanism, mediated by modifications of the
composition and number of N-linked and O-linked oligosac-
charide chains, which may be responsible for changes in the
hormonogenic efficiency at both hTg termini, affecting the
overall ratio of T4 over T3 formation in hTg. For hormone
release to occur, Tg must be internalized into thyroid follicular
cells and degraded in lysosomes. A part of Tg, internalized via
the endocytic receptormegalin, bypasses lysosomes and is tran-
scytosed across cells, to be secreted from the basolateral pole
(43). Tg binding to megalin is facilitated by accessory interac-
tions with heparan-sulfate proteoglycans on the surface of thy-
roid cells (44, 45). Experiments are in progress to determine
whether chondroitin 6-sulfate units may interfere with the
binding of hTg to megalin. Conceivably, the addition of chon-
droitin 6-sulfate to hTg, besides improving the yield of active
hormone, may also prevent the nonproductive internalization
of hTg by transcytosis.
Furthermore, we identified two sites, one between Lys2714
andGly2715 and the other between Lys2745and Thr2746, near the
site of chondroitin 6-sulfate addition, whichwere susceptible to
limited proteolysis with trypsin. Our data show that the former
was protected from proteolysis in hTg-CS but not in hTg-CS0.
Both the hormone-forming advantage of hTg-CS over hTg-CS0
and the resistance of peptide bond 2714–2715 to proteolysis
persisted after digestion of hTg-CS with chondroitinase ABC.
Such findings indicate that the residual oligosaccharide that
was left in situwas sufficient for the observed effects. This is not
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surprising with respect to proteolysis, becauseO-linked mono-
and disaccharides were able to protect specific cleavage sites
from cathepsin L (12). Moreover, the production of proteolytic
fragments by an oxidative cleavage mechanism was repeatedly
observed in the course of Tg iodination both in vitro (46, 47)
and in vivo (48). The protection from the occurrence of such
cleavages in the carboxyl-terminal end of hTg, possibly
afforded by the oligosaccharide chain at Ser2730, even in its
residual form after digestion with chondroitinase ABC, might
contribute to improve the hormone yields. Verification of this
hypothesis will be the aim of future work. It is worth noticing
that the product of digestion of hTg-CS with chondroitinase
ABCdiffered fromnative hTg-CS0, because this enzymehydro-
lyzes the -(134)-glycosidic bonds between N-acetyl-D-galac-
tosamine 6-sulfate and D-glucuronic acid, thus removing -Gl-
cUA-(133)-GalNAc-6S disaccharides, while leaving in situ a
GlcUA-Gal-Gal-Xyl linkage oligosaccharide. Moreover, Has-
call et al. (49) reported that the disaccharide closest to the link-
age oligosaccharide in chondroitin 4-sulfate resisted digestion
by chondroitinase ABC. Our data entail, even though some of
the hTgmolecules in theQ1 peakmight contain short oligosac-
charide chains of this kind, that all the hTg molecules from the
Q2 peak digested with chondroitinase ABC contained residual
stubs, in a heterodimeric or even in a homodimeric form.
The reported effects on proteolysis are in support of a possi-
ble modifying influence of the chondroitin 6-sulfate unit in the
processing of hTg byAPCs, and in the ability of hTg to function
as an autoantigen, particularly because the chondroitin 6-sul-
fate unit was located within an epitope-rich region, harboring
several T cell-related epitopes, capable of causing EAT in genet-
ically susceptible mice, and B cell-related epitopes, recognized
by circulating autoantibodies of patients with AITD (reviewed
inRef. 1). The effects of oligosaccharide chains on the activity of
proteolytic enzymes involved in antigen processing and on the
affinity of epitope binding tomajor histocompatibility complex
or T cell receptormolecules have been reviewed (11).O-Linked
mono- and disaccharides in tumor-associated glycoprotein
MUC1 restricted the repertoire of the epitopes produced
and/or presented in a site-specific manner, either by limiting
the proteolytic accessibility of the protein (12) or by preventing
epitope recognition by a peptide-specific T cell hybridoma (13).
N-Linked oligosaccharide chains inhibited the generation of a
self-epitope fromglutamate receptor subunit 3 (14) and of cyto-
toxic lymphocyte-specific epitopes from influenza A nucleo-
protein (15). Moreover, a keratan sulfate chain masked an
arthritogenic T cell epitope in the G1 domain of aggrecan,
whereas the depletion of multiple chondroitin sulfate side
chains generated clusters of chondroitin sulfate stubs, which
activated specific B cells to function as APCs (16). We expect
that the chondroitin 6-sulfate chain of hTg may inhibit the
processing of hTg peptide 2731–2744 (amino acid numbering
as per Ref. 29), known for its ability to stimulate in vitro strong
proliferative responses and the adoptive transfer of EAT by
splenic lymphocytes of CBA mice immunized with mouse Tg
(50). Other epitopes might be abrogated by the chondroitin
6-sulfate unit, should their generation require cleavage in the
vicinity of Ser2730, within a range including the Lys2714–Gly2715
peptide bond on the amino side.
In addition, significant effects of chondroitin sulfate oligo-
saccharide chains on cellular immune responses have beendoc-
umented. A small percentage (2–5%) of invariant chain mole-
cules, associatedwith class IImajor histocompatibility complex
molecules, are modified with the addition of a single chon-
droitin sulfate chain at Ser291 (Ii-CS). In this form, they remain
associated with class II molecules at the surface of APCs (51,
52), where they act as accessory molecules in antigen presenta-
tion, facilitating the interactions between APCs and T cells, and
greatly enhancing class II-dependent allogeneic and mitogenic T
cell responses (17). Such effects occur through interactions of
Ii-CS with CD44 on responding T cells, as they can be inhibited
both by anti-CD44 antibodies, and by a soluble form of CD44
(CD44Rg), which binds Ii-CS directly (17). Treatment of spleen
cells with xyloside, which inhibits GAG addition (53), interferes
with their antigen-presenting capabilities (54). Serglycins, small
proteoglycans stored in secretory granules of hematopoietic cells,
activate the CD3-dependent release of cytokines and proteases
fromCD44-positivecytotoxic lymphocytic clones (18)by interact-
ing with CD44 through their chondroitin 4-sulfate and 6-sulfate
side chains (19). Moreover, CD44 binding to aggrecan, a major
proteoglycan of the cartilage matrix, through the chondroitin 4-
and 6-sulfate side chains of the latter, can trigger the oligomeriza-
tionofCD44moleculesandtheactivationof intracellular signaling
(20). In keeping with these suggestions, preliminary results indi-
cate that the chondroitin 6-sulfate oligosaccharide unit signifi-
cantly affects the immunopathogenic capacity of hTg inCBA/J(H-
2Ak) mice by a complexmechanism.3
Finally, the close clinical association between Graves hyper-
thyroidism and thyroid-associated ophthalmopathy (TAO) led
to the hypothesis that the latter might be the result of an auto-
immune response against orbital autoantigen(s) that are also
present in the thyroid. Candidate antigens, besides the TSH
receptor, include Tg (55). Some authors detected hTg in the
orbital tissues of patients with TAO and hypothesized that it
might be transferred there via thyroid-orbit connections evi-
denced by lymphography (56). hTg was found prevailingly in
fibroadipose tissue (57). It was proposed that the ability of hTg
to bind to GAGs, including chondroitin sulfate B and C, might
mediate its localization in orbital tissues, where it might func-
tion as a target of immune responses directed against the thy-
roid (58). Metachromatic GAGs accumulate in TAO and thy-
roid-associated dermopathy (55). Edematous connective
perimysial tissues of patients with TAO are composed mainly
of hyaluronan and chondroitin sulfate (59). Accumulation of
GAGs and adipose tissue expansion is apparent in the fatty
connective tissue of the posterior orbit (60). In our opinion, the
presence of an integral GAG chain, in a fraction of hTg mole-
cules, may represent a mechanism by which autoaggressive
responses against hTg may spread to connective tissue antigens
with sharedGAGchains, particularly in the event that the synthe-
sis of both be quantitatively and/or qualitatively dysregulated.
Proving this hypothesis will require the fine structural character-
izationof the chondroitin 6-sulfate chains of hTg andof theGAGs
3 M. Conte, A. Arcaro, D. D’Angelo, A. Gnata, F. Fulciniti, S. Formisano, and F.
Gentile, manuscript in preparation.
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of orbital connective tissues from patients with TAO, and the
demonstration of cross-reacting B and/or T cell clones.
In conclusion, a single chondroitin 6-sulfate chain linked to
Ser2730 in a relevant fraction of hTg molecules influences both
the hormone-forming efficiency and the proteolytic accessibil-
ity of the carboxyl-terminal region of hTg. These effects may
bear consequences on thyroid homeostasis and autoimmunity.
Further work will be aiming to determine the following:
1) What are the physiological limits of hTg-CS abundance in
hTg? 2)How is the synthesis of the chondroitin 6-sulfate unit of
hTg regulated, particularly regarding the role of TSH? May
changes of hTg-CS abundance mediate thyroid adaptation to
iodine deficiency or inherited defects of thyroid hormone syn-
thesis or secretion? 3) Do any correlations exist between thy-
roid function and variations in the hTg-CS/hTg-CS0 ratio or in
the chondroitin 6-sulfate chain length, as analyzed by gel elec-
trophoresis of the oligosaccharide units released from hTg by
-elimination, in comparisonwith appropriate standards? 4)How
does thechondroitin6-sulfateunit influence theprocessingofhTg
by APCs and cellular immune responses to hTg in vivo? It is our
opinion that a systematic investigation may shed light on the
pathogenesis of thyroid diseases, particularly AITD.
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